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2. List of abbreviations 
 
 
5-HT 5-hydroxytryptamine (or serotonin) 
7β-forskolin 7-deacetyl-7-(O-N-methylpiperazino)-γ-butyryl-forskolin 
7TM 7-transmembrane spanning domain 
ACh acetylcholine 
aCSF artificial cerebrospinal fluid 
AMN082 N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride 
APPA 3-aminopropylphosphinic acid 
baclofen β-p-chlorophenyl GABA 
CaM calmodulin 
CAM constitutively active mutant 
cAMP  cyclic AMP, cyclic 3',5'-adenosine-monophosphate 
Calhex 231 chlorophenylcarboxamide or (1S,2S,1'R)-N1-(4-clorobenzoyl)-N2-[1-(1-
naphtyl)ethyl]-1,2-diaminocyclohexane 
CaSR calcium-sensing receptor 
CGP13501 2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenaldehyde 
CGP35348 3-aminopropyl-(diethoxymethyl)-phosphinic acid 
CGP47656 3-aminopropyl-(difluoromethyl)-phosphinic acid 
CGP52432 3[[(3,4-(dichlorophenyl)methyl]amino)-propyl](diethoxymethyl) 
phosphinic acid 
CGP56999 [3-[1-(R)-[[3-cyclohexylmethyl)hydroxyphosphinyl]-2-(S)-
hydroxypropyl]amino]ethyl]-benzoic acid 
CGP62349 [3-[1-(R)-[[(2S)-2-hydroxy-3-[hydroxyl[4-
methoxyphenyl]methyl]phosphynyl]propyl]amino]ethyl]-benzoic acid 
CGP7930 2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethyl-propyl)-phenol 
CHO Chinese hamster ovary 
Cinacalcet N-2-(1-naphthyl)ethyl-3-(3-trifluormethylphenyl)propylamine 
CNS central nervous system 
CPA N6-cyclopentyladenosine 
CRF1 Corticotropin-releasing factor type I receptor 
CRH of CRF corticotropin-releasing hormone or factor 
DA Dopamine 
DFB 3,3'-difluorobenzaldazine 
DIV day in vitro 
DMEM Dulbecco’s modified eagle medium 
DMSO dimethyl sulfoxide 
FLIPR  fluorescence imaging plate reader 
G-protein guanine nucleotide-binding protein 
GABA  γ-aminobutyric acid 
GAP GTPase activating protein 
GHB γ-hydroxybutyric acid 
GIRK (or Kir3) inwardly rectifying potassium channels 
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GPCR  G-protein-coupled receptor 
GRK GPCR kinase 
GS39783 N,N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine 
GTP(γ)S guanosine 5'-O-(3-thiophosphate) 
HBSS Hanks’ buffered salt solution 
HEK human embryonic kidney 
HTS high-throughput screen 
i2 or i3 intracellular loop 2 or intracellular loop 3 
IBMX  isobutyl-methylxanthine 
IP inositol-phosphate 
IPSC inhibitory postsynaptic current 
Kir3 (or GIRK) inwardly rectifying potassium channels 
LY354740 (1S,2S,5R,6S)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 
LY544344 [(1S,2S,5R,6S)-2-[(2'S)-(2'-amino)propionyl]aminobicyclo[3.1.0]hexane-
2,6-dicarboxylic acid hydrochloride] 
M1-M5 muscarinic acetylcholine receptor type 1-5 
mGluR metabotropic glutamate receptor 
NPS2143 N-[R-2-hydroxy-3-(2-cyano-3-chlorophenoxy)propyl]-1,1-dimethyl-2-(2-
naphthyl)ethylamine 
PACAP pituitary adenylate cyclase activating protein 
PBP periplasmic binding protein 
PBS phosphate-buffered saline 
PD81’723 2-amino-4,5-dimethyl-3-thienyl-[3(trifluoromethyl)-phenyl]methanone 
PIP3 phosphatydilinositol-3,4,5-triphosphate 
PLC phospholypase C 
PKA cAMP dependent protein kinase or protein kinase A 
PKC protein kinase C 
PTH parathyroid hormone 
R-121919 3-[6-(dimethylamino)-4-methyl-pyrid-3-yl]-2,5-dimethyl-N,N-dipropyl-
pyrazolo[2,3-a]pyrimidin-7-amine 
RGS regulator of G-protein signaling 
RIA  radioimmunoassay 
SCH50911 (2S)-(+)-5,5-dimethyl-2-morpholineacetic acid 
SPA  scintillation proximity assay 
T62 1-amino-4,5,6,7-tetrahydrobenzo(β)thiophen-3-yl 
TCM  ternary complex model 
VFTM  Venus flytrap module 
VTA ventral tegmental area 
WGA wheat germ agglutinin 
WT wild-type 
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3. Summary 
Allosteric modulators of G-protein coupled receptors (GPCRs) interact with binding sites on 
the receptor molecule that are topographically distinct from the classic orthosteric site. Having 
only a marginal effect by themselves, they induce conformational changes of receptors that 
result in the modulation of agonist-induced function in either a stimulating or an inhibiting 
way, depending on whether they are positive or negative allosteric modulators, respectively. 
Their mechanism of action is, thus, in synchrony with the frequency and the magnitude of 
physiological signaling. This is the main reason why allosteric modulators are considered to 
have a better side-effect profile and to be less prone to induction of tolerance than classic 
orthosteric agonists. Allosteric modulators have gained significance in the scientific 
community in the past decade. 
This thesis comprises four parts and focuses on the positive allosteric modulation of the 
GABAB receptors. Two prototypal positive allosteric modulators CGP7930 and GS39783 
have recently been discovered and characterized in Novartis Pharma (Urwyler et al. 2001 and 
2003). A number of questions regarding their further characterization, namely their effects on 
orthosteric ligands with distinct intrinsic properties, the role allosteric modulation plays in 
GABAB receptor desensitization and biochemical effects of GS39783 in vivo are addressed in 
this thesis. 
 
Mechanisms of allosteric modulation at GABAB receptors by CGP7930 and GS39783: 
effects on affinities and efficacies of orthosteric ligands with distinct intrinsic properties 
The first part of this thesis shows that, as it is predicted by theoretical models of receptor 
activation, all GABAB ligand species are amenable to allosteric modulation. A number of  
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selective GABAB receptor ligands were tested in the presence and the absence of positive 
allosteric modulators CGP7930 and GS39783 in in vitro assays, such as radioligand binding, 
GTP(γ)S and cellular cyclic AMP (cAMP) measurements. A decrease in affinity of 
antagonists was observed in radioligand binding experiments, without a change of the 
receptor number, oppositely to increases in affinity of partial agonists. In the GTP(γ)S 
experiment the presence of CGP7930 and GS39783 revealed intrinsic efficacies for 
CGP35348 and 2-OH-saclofen, two “silent” GABAB receptor antagonists. In the cAMP 
measurements, an even more sensitive experimental system, the two abovementioned 
compounds acted as partial agonists, with increased efficacies in the presence of positive 
allosteric modulators. Inverse agonistic tendencies were observed with the “silent” antagonist 
CGP52432. In this part of the thesis, the positive allosteric modulators GS39783 and 
CGP7930 have been shown to be useful experimental tools for elucidating intrinsic properties 
of orthosteric ligands.  (Chapter 5, Section 5.1.) 
 
Receptor activation involving positive allosteric modulation, unlike full agonism, does 
not result in GABAB receptor desensitization: an in vitro study 
To inspect the role of the positive allosteric modulator GS39783 in GABAB receptor 
desensitization, receptor function and cell surface receptor density were examined in a 
recombinant GABAB cell line and in primary neuronal cultures upon persistent treatments 
with GABAB agonists, and combinations of agonists and GS39783. While the GABAB 
receptor desensitized after lasting pretreatments with saturating concentrations of GABAB 
agonists GABA or R(-)-baclofen, the combined treatment with low concentration of agonists 
and GS39738 did not lead to desensitization, despite activating the receptor to the same extent 
as desensitization-inducing agonists. These results indicate that it is the degree of occupancy 
of the orthosteric binding site that determines desensitization, rather than the degree of 
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receptor activation. Desensitization experiments with the GABAB receptor and GS39783 in 
this study demonstrate that, according to predictions, positive allosteric modulation as a 
therapeutic principle may indeed be more promising than orthosteric agonism, having less 
propensity for developing tolerance due to receptor desensitization.  (Chapter 5, Section 5.2.) 
 
Changes in behavior of allosteric and orthosteric GABAB receptor ligands after a 
continuous agonist pretreatment 
Investigating the effects of GS39783 on GABAB receptor desensitization, interesting findings 
revealed changes in ligand behavior upon receptor desensitization in the GABAB recombinant 
cell line. “Silent” antagonists such as CGP62349, CGP52432, CGP56999 and SCH50911 
were found to have inverse agonistic properties, the partial agonist 2-OH-saclofen was devoid 
of positive intrinsic efficacy and the positive allosteric modulator GS39738 was acting in a 
manner of an allosteric agonist. The possibility of residual GABA present from the 
pretreatment and responsible for these effects was ruled out. All observed phenomena point 
toward an increase in constitutive activity of the receptor. Increase of constitutive receptor 
activity after lasting agonist pretreatments have previously been reported for the β2-adrenergic 
and the opioid receptors. This is, however, the first such finding for the GABAB receptor, 
which might be important in elucidating the valence of orthosteric ligands as well as their 
effects upon a chronic drug treatment. It would be interesting to see whether the same 
phenomena would be observed also for other members of GPCR family 3.   (Chapter 5, 
Section 5.3.) 
 
The positive allosteric modulator GS39783 enhances GABAB receptor-mediated 
inhibition of cyclic AMP formation in rat striatum in vivo 
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In the last part of this thesis, I provide the first biochemical evidence of in vivo activity of a 
positive allosteric modulator of GPCRs. By using in vivo microdialysis in striata of freely 
moving rats, changes in extracellular levels of cAMP following GABAB receptor activation 
were monitored. Locally applied GABAB receptor agonist R(-)-baclofen inhibited cAMP 
formation stimulated by 7β-forskolin in a concentration-dependent manner, which was 
reversed by the co-application of the selective GABAB antagonist CGP56999. Orally applied 
positive allosteric modulator GS39783 lacked effects on its own but, together with a threshold 
concentration of R(-)-baclofen, it significantly decreased cAMP formation in a dose-
dependent fashion. Effects of GS39783 were revoked with CGP56999, showing dependence 
on concomitant GABAB receptor activation by an agonist and suggesting allosteric 
modulation as its mechanism of action in vivo.  (Chapter 5, Section 5.4.) 
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4. Introduction 
The focus of this thesis is allosteric modulation of the GABAB receptor. There are two 
positive allosteric modulators of the GABAB receptors, CGP7930 and GS39783, that have 
recently been discovered and characterized in Novartis Pharma AG (Urwyler et al. 2001 and 
2003). I was interested in further biochemical characterization of the allosteric mechanism of 
action of these compounds. 
In this introduction, I will address allosteric modulation in general and potential advantages of 
the use of allosteric modulators over orthosteric ligands in receptor activation. Subsequently, 
the main points of the GABAB receptor discovery and its unique structure and function, 
potential role in central nervous system (CNS) disorders and mechanisms of desensitization 
will be outlined. Finally, I will describe the actions of GABAB positive allosteric modulator 
and summarize the questions addressed in this thesis. 
 
  
4.1. Allosteric modulation of G-protein-coupled receptors (GPCRs): a novel 
therapeutic principle 
 
4.1.1. General aspects of allosteric modulation 
The term allosteric originates from Greek, with άλλος (allos) meaning other and στερεός 
(stereos) meaning shape. It describes different mechanisms by which protein functions can be 
regulated and fine-tuned in either a positive or a negative direction. The initial observation of 
the phenomenon of allostery was made by C. Bohr in his early studies on hemoglobin in 
 14 
 
 
 
 
1904, when he revealed that hemoglobin could simultaneously bind more than one molecule 
of oxygen and introduced the term cooperativity referring to the interactions between the 
binding of oxygen molecules (Bohr et al. 1904). The term allosteric has, however, been 
coined in 1965 by J. Monod, J. Wyman and J.P. Changeux to explain control of enzyme 
activity by a regulatory molecule that binds to sites that are distinct and often removed from 
the catalytic site and that exerts its action through conformational changes (Monod et al. 
1965). One classical example of an allosteric interaction in pharmacology is the effect of 
benzodiazepines (e.g. diazepam) on GABAA receptors, which enhance receptor function by 
binding to a separate site on the receptor. 
When it comes to receptor function, allosteric modulators are substances that bind to receptors 
at the site termed the allosteric binding site (the alternative binding site), which is 
topographically distinct from the orthosteric (Greek ορθός or orthos means correct) binding 
site that binds orthosteric ligands, either orthosteric agonists (e.g. the natural ligands) or 
competitive antagonists. The binding of an allosteric modulator to its binding site induces a 
conformational change of the receptor. The transmission of this conformational change from 
the allosteric to the orthosteric binding site and/or directly to effector coupling sites enables 
allosteric ligands to modulate receptor activity. A reliable proof of a true allosteric mechanism 
is a demonstration of a change in affinity of an orthosteric ligand in the presence of the 
alleged allosteric agent by utilizing kinetic (non-equilibrium) radioligand binding experiments 
(Christopoulos and Kenakin 2002). However, allosteric modulators can either affect affinity 
(or potency) of orthosteric ligands, their efficacy or both. There are also examples of allosteric 
agonism or allosteric inverse agonism; these compounds bind to the allosteric binding site on 
the receptor and stimulate the receptor on their own, independently of orthosteric ligands 
(Figure 1). This thesis, however, focuses only on modulating compounds depicted by 
mechanisms (1) and (2)  on Figure 1, and not on allosteric agonists (mechanism (3) on Figure 
1).  
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Figure 1. The binding of an allosteric modulator can either affect the binding affinity of an orthosteric 
ligand (1) and/or the orthosteric ligand efficacy (2). Allosteric agonists can directly activate the 
receptor on their own (3). Taken from (Langmead and Christopoulos 2006), with permission from 
Elsevier. 
 
There are numerous advantages of allosteric modulators over conventional orthosteric ligands. 
To begin with, upon their binding to the allosteric site in the absence of an orthosteric ligand, 
allosteric modulators on their own usually affect the signaling cascade of the receptor in a 
limited fashion (which can only be detected in very sensitive experimental systems) or not at 
all. This means that not the whole population of receptors is affected by the binding of the 
allosteric species, but only the fraction of receptors that is activated by the endogenous 
agonist; thus is the action of the allosteric drug in spatial and temporal synchrony with 
physiological stimulation (Figure 2). In this light, the probability of the target receptor 
desensitizing (which is one of the mechanisms for acquired tolerance) is smaller even in a 
continuous presence of an allosteric agent, when compared to continuous activation via the 
orthosteric ligand. In addition, for the same reason allosteric modulators are expected to have 
a better side-effect profile than agonists and are less likely to elicit toxic effects due to an 
overdose.  
Moreover, since the allosteric binding sites are usually situated in non-conserved regions of a 
receptor, allosteric agents can often be selective for a certain receptor subtype, which is more 
unlikely for orthosteric ligands, that bind to highly conserved sites on receptors. This could be 
explained with less evolutionary pressure for the conservation of allosteric binding sites, most 
likely due to the lack of endogenous allosteric ligands. An interesting variant of this notion  
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Figure 2. An allosteric modulator is a more physiological alternative when compared to a synthetic 
agonist. An allosteric modulator acts only in the presence of an endogenous agonist, mimicking  the 
duration (and the spatial organization) of the natural signaling. Taken from (Soudijn et al. 2004), with 
permission from Elsevier.
 
 
 
implies different degrees of cooperativity between the orthosteric and the allosteric site at 
different receptor subtypes leading to absolute subtype selectivity, introduced by the group of 
N.J.M. Birdsall (Lazareno et al. 1998). A remarkable example of this phenomenon was 
demonstrated at the muscarinic acetylcholine (ACh) receptors, which exist in five subtypes 
(M1-M5). Whereas thiochrome was shown to bind to all subtypes, it was absolutely selective 
for M4, by increasing the affinity for ACh 3- to 5-fold, while having only negligible effects 
(neutral cooperativity) on ACh binding at the other four muscarinic receptor subtypes 
(Lazareno et al. 2004). 
Further, it has been shown that different GPCR conformations can stimulate distinct signaling 
pathways (see Kenakin 2003; Perez and Karnik 2005; Maudsley et al. 2005 for reviews). It is 
thus possible for the activation involving an allosteric agent to activate a particular signaling 
pathway. In fact, agonist-directed trafficking has recently been demonstrated for the allosteric 
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agonist of the metabotropic glutamate receptor (mGluR) type 7 AMN082. Namely, Suzuki et 
al. (2007) have shown that while AMN082 inhibited cAMP formation by activating the 
mGluR7, it failed to induce intracellular Ca2+ mobilization when the receptor was artificially 
coupled to the phospholipase C (PLC) pathway. In addition, one part of the work presented in 
this thesis, regarding continuous exposure of the GABAB receptor to the positive allosteric 
modulator GS39783, goes in this direction (see Chapter 5, Section 5.3.). 
Finally, allosteric ligands offer new opportunities to medicinal chemistry aiming at receptors 
considered to be problematic drug targets. Such are for example large molecular weight 
ligand (e.g. peptide) receptors, regarded as difficult targets for small molecules due to the size 
of their binding sites or the calcium-sensing receptor (CaSR), orthosteric agonists of which 
are inorganic cations (see Christopoulos 2002; Jensen and Spalding 2004; May et al. 2007; 
Langmead and Christopoulos 2006 for reviews). 
Another example where allosteric modulation provides new possibilities for medicinal 
chemistry are the mGluRs. There are eight known mGluRs divided into three families, with 
L-glutamate being a natural ligand for all the receptor subtypes (Conn and Pin 1997). There 
are two main hurdles for developing orthosteric ligands for mGluRs, namely subtype 
selectivity and physicochemical properties of ligands. As mentioned above, because of the 
highly conserved orthosteric binding site, it is extremely difficult to develop subtype specific 
orthosteric ligands. Moreover, all the known orthosteric ligands of mGluRs are amino acid 
derivatives and it seems that this structural element is crucial for their binding and efficacy. 
Unfortunately, amino acid-like structures consist of charged and polar moieties, which is the 
reason for both their limited absorption from the gut and their poor brain penetrability. The 
development of allosteric modulators has thus proven to be a promising alternative solution 
for specific targeting of mGluRs subtypes and elucidation of their therapeutical potential in 
diseases (Ritzen et al. 2005). 
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To summarize, the fact that there are less structural constraints for compounds with allosteric 
properties has opened new avenues in medicinal chemistry. The attractiveness of GPCR 
allosteric modulators as novel drug targets has resulted in an increasing body of literature on 
the subject in recent years, which is represented by a large number of review articles 
(Christopoulos 2002; Christopoulos and Kenakin 2002; Rees et al. 2002; Soudijn et al. 2002; 
Conigrave and Franks 2003; Birdsall et al. 2004; Christopoulos et al. 2004; Jensen and 
Spalding 2004; May et al. 2004 and 2007; Soudijn et al. 2004; Bowery (ed), 2006; Gao and 
Jacobson 2006; Langmead and Christopoulos 2006; Noeske et al. 2006; Schwartz and Holst 
2006). 
It is worthwhile looking at mechanisms of allosteric modulation in the light of classical and 
more recent receptor models. 
 
4.1.2. Theoretical receptor models 
  a) The two state model of receptor activation (Figure 3) 
The two-state model of receptor activation illustrates the intrinsic efficacies of orthosteric 
ligands, but does not account for allosteric modulation (Leff 1995). The major assumption in 
the two state model is that there are two interchangeable conformations of a receptor: the  
 
A + R    A + R *    
                            
         L    
  
    K    αK 
 
                           αL  
 
AR    AR* 
 
 
Figure 3. The two-state model of receptor activation. R: resting state of the receptor, R*: active state 
of the receptor, A: ligand, K: binding constant of A, L: receptor isomerisation constant, α: intrinsic 
efficacy of A. Taken from (Urwyler, Gjoni et al. 2005) with permission from Elsevier.  
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resting (R) and the active state (R*) (Figure 3). The exchange between the two states is 
characterized by an equilibrium constant L. The existence of R* in an absence of the ligand 
(A) is the basis for constitutive activity. The constant K describes the binding affinity of the 
ligand (A) to the receptor (R). If the ligand bound stabilizes the active (R*) over the resting 
state (R), the equilibrium is shifted toward the active state (α >1) and the ligand is an agonist. 
Contrarily, an inverse agonist prefers and stabilizes the inactive form of the receptor and has 
an α value smaller than 1. A silent antagonist binds to both states of the receptor with equal 
affinity and does not affect the proportions of the active and the resting state (α =1), but 
inhibits agonist binding by blocking the binding site. 
 
  b) The ternary complex model (TCM) (Figure 4) 
The TCM was originally developed to describe the changes in agonist affinity induced by the 
receptor-G-protein coupling, a prototype example of allosteric interactions (De Lean et al. 
1980). It can, however, also be applied to allosteric modulation by small molecules. The TCM 
takes into consideration the influence on binding affinity that the allosteric ligand (B) has on  
 
 
A + R + B     A + RB 
 
        M 
  
    K     γK 
 
 
       γM 
 
     AR + B      ARB 
 
Figure 4. The ternary complex model of receptor activation. R: receptor, A: orthosteric ligand, B: 
allosteric ligand, K: binding constant of A, M: binding constant of B, γ: binding cooperativity between 
A and B. Taken from (Urwyler, Gjoni et al. 2005) with permission from Elsevier. 
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the orthosteric ligand (A) when it binds to the receptor (R) to a distinct binding site. The 
constant K depicts the binding affinity of the orthosteric ligand (A) for the receptor and M is 
the affinity constant of the allosteric ligand B toward the receptor R. The binding 
cooperativity between A and B is described by the factor γ. This model, unlike the two-state 
model, takes into account allosteric interactions, but it does not account for the intrinsic 
efficacy of the orthosteric ligand, i.e. the activation of the receptor by ligand binding.  
    
  c) The allosteric two-state model (Figure 5) 
 
 
         βM 
   A + B + R*                             A + BR* 
 
         L                                                            βL 
                                   αK          
        
                                          M                                                       αγδK 
A + B + R     A + RB 
 
     
 
  
  B + AR*                      AR*B 
       βγδM  
K       αL                      γK 
                                                                                           αβδL 
   
 
AR + B      ARB 
   γM 
 
 
Figure 5. The allosteric two-state model of receptor activation. R: resting state of the receptor, R*: 
active state of the receptor, A: orthosteric ligand, B: allosteric ligand, K: binding constant of A, L: 
receptor isomerisation constant, M: binding constant of B, α: intrinsic efficacy of A, β: intrinsic 
efficacy of B, γ: binding cooperativity between A and B, δ: activation cooperativity between A and B.  
Taken from (Urwyler, Gjoni et al. 2005) with permission from Elsevier.
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Although the “allosteric ternary complex model” (ATCM) (Lefkowitz et al. 1993) was the 
first attempt to combine the two previous models, the allosteric two-state model described by 
Hall (2000), allows for the first time the allosteric modulator to simultaneously affect the 
affinity of orthosteric ligands as well as their efficacy. The extension of the two-state model 
of receptor activation introduces the allosteric constant δ, by which the intrinsic efficacy of 
the orthosteric ligand α is modified. This model treats the allosteric interactions strictly in 
numerical terms, i.e. the constants γ and δ are independent of the qualitative nature of α. This 
means that the orthosteric agonist (intrinsic efficacy of which is described by α) can be a 
partial or full agonist, a silent antagonist or an inverse agonist, with and all the chemical 
entities equally amenable to allosteric modulation. This topic is addressed and further 
discussed in Chapter 5, Section 5.1. of this thesis or (Urwyler, Gjoni et al. 2005). 
 
 
4.2. The GABAB receptor 
GABA is the main inhibiting neurotransmitter in the CNS. It modulates the neuronal activity 
by mediating its action via GABAA, GABAB and GABAC receptors. GABAA and GABAC 
receptors are ligand-gated ion channels while the GABAB receptor is a metabotropic receptor 
coupled to heterotrimeric G-proteins. The GABAA receptor, a pentameric ligand-gated ion 
channel that mediates a fast neuronal inhibition (hyperpolarization) by enabling the influx of 
chloride ions into the postsynaptic terminal, is known longest. There are many drugs currently 
on the market that target the GABAA receptor, namely benzodiazepines (e.g. diazepam) or 
barbiturates (such as pentobarbital) which are widely used in the clinical practice as 
anticonvulsants, myorelaxants, sedatives and anesthetics. It was believed that the GABAA 
receptor was the only GABA receptor until the late 1970ies, when the existence of the 
GABAB receptor was first proposed (Bowery et al. 1980). The GABAC receptors were 
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postulated even later, in the 1990s, as mediators of the GABA response that is insensitive to 
GABAA and GABAB antagonism (Johnston 1996). 
 
4.2.1. The discovery and structure of the GABAB receptor 
The prototypical GABAB agonist baclofen (β-p-chlorophenyl-GABA) has been in clinical 
practice as an antispastic agent under the name of Lioresal for more than thirty years, long 
before GABAB receptors were known as a distinct entity (see more in Subsection 4.2.4.). 
In the late seventies of the 20th century the group of N. G. Bowery observed that the actions of 
GABA and baclofen to inhibit noradrenaline, dopamine and serotonin release were not 
blocked by the known GABA antagonist bicuculline, nor mimicked by GABA-mimetics such 
as isoguvacine or 3-aminopropanesulphonic acid. Moreover, they were independent of the 
concentrations of chloride ions, but not of Mg2+ and Ca2+. As a consequence the novel 
baclofen-sensitive bicuculline-insensitive receptor termed the GABAB receptor was 
postulated (Bowery et al. 1980). 
The main breakthrough in the GABAB receptor research occurred 17 years later, with its 
cloning by the group of B. Bettler (Kaupmann et al. 1997). The delay in the cloning of the 
receptor was due to the fact that there were difficulties in coupling of the receptor to its 
effector systems in heterologous cells and the lack of pharmacological tools suitable for 
expression cloning at the time (see Bettler et al. 2004). Only after an iodinated high-affinity 
GABAB ligand was finally available, two isoforms of the same protein, structurally similar to 
the mGluRs, GABAB(1a) and GABAB(1b) were discovered using a radioligand-binding 
screening approach (Kaupmann et al. 1997). Rat GABAB(1a) and GABAB(1b) proteins are 
composed of 960 and 844 amino acids, respectively, with the only difference being the 
presence or the absence of the so-called “Sushi repeats” (or “short consensus repeats”) at their 
extracellular NH2-terminal domain (N-terminus), respectively. It was found later that the 
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human GABAB(1a/b) proteins share 99% sequence identity with the rat GABAB(1a/b) proteins 
(Kaupmann et al. 1998b). Despite the success in isolating two GABAB receptor proteins, it 
was noted that there was a hundred-fold decrease in binding affinities of GABAB agonists 
when compared to the wild-type (WT) receptors. In addition, there was little functional 
response upon agonist binding and only at agonist concentrations which were saturating in 
native tissues. This aroused an interest of the scientific community, which soon afterward 
resulted in the cloning of another GABAB receptor protein, termed GABAB(2), that shared 
35% homology to the first two GABAB proteins. The discovery was made by six groups 
simultaneously (Kaupmann et al. 1998a; Jones et al. 1998; Kuner et al. 1999; Martin et al. 
1999; Ng et al. 1999; White et al. 1998). 
 
Figure 6.  Phylogenetic analysis of human family C GPCRs. Taken from (Bettler et al. 2004), with 
permission of the American Physiological Society. 
 
The GABAB receptor belongs to the GPCR family 3 (or C), together with eight mGluRs, the 
CaSR, taste and pheromone receptors and five orphan receptors (Figure 6) (Pin et al. 2003). 
The peculiarity of the GABAB receptor is the fact that in order to be functional it needs to be a 
heterodimeric complex, composed of the GABAB(1a) or the GABAB(1b) and the GABAB(2) 
subunit (Figure 7). 
As the other members of GPCR family 3, the GABAB receptors possess the seven 
transmembrane spanning domain (7TM), an intracellular COOH-terminal tail (C-terminus), 
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which has been shown to bind many proteins that regulate the GABAB receptor function (see 
Bettler et al. 2004 and Emson 2007 for reviews) and a large extracellular NH2-terminal 
domain (N-terminus) that contains the orthosteric site for agonist/competitive antagonist 
binding, which, like it is the case with mGluRs, is related to the bacterial periplasmic binding 
proteins (PBP) (O'Hara et al. 1993). However, in contrast to the mGluRs, the N-terminal part 
of the GABAB subunits lacks a cysteine-rich region that connects the PBP-like domain to the 
TM1 (Malitschek et al. 1999). The agonist-binding site consists of two large globular lobes 
connected by a hinge region. A conformational change occurs in the hinge region upon 
agonist binding which brings the two lobes closer together trapping the agonist similarly to 
the trapping of the insect by a carnivorous plant called the Venus flytrap (Galvez et al. 1999; 
Bessis et al. 2000; Galvez et al. 2000a; Bernard et al. 2001; Kniazeff et al. 2004). Even  
 
 
 
Figure 7. A cartoon of the GABAB receptor. GABAB(1a) (green) and GABAB(2) (grey) form a 
heterodimer mainly interacting via the C-terminal tail forming a coiled-coil domain. Both GABAB(1) 
and GABAB(2) subunits contain a VFTM, but only the VFTM of GABAB(1) is able to bind orthosteric 
ligands. In addition, the N-terminus of GABAB(1a) has two Sushi motifs, which are missing in the 
GABAB(1b) isoform. The GABAB(2) subunit is crucial for the interaction with the G-protein (blue) and 
it also contains the binding site for the positive allosteric modulator GS39783 (Dupuis et al. 2006). 
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though both the GABAB(1) and the GABAB(2) subunits contain the “Venus flytrap module” 
(VFTM), only the GABAB(1) subunit is able to bind orthosteric ligands. The amino acids 
critical for ligand binding in the VFTM of the GABAB(2) subunit have not been conserved 
(Galvez et al. 2000a). 
The functional importance of the presence of the GABAB(2) receptor subunit lies in the surface 
trafficking of the GABAB(1) receptor subunit and the GABAB receptor coupling to effector 
systems and signal transduction. The GABAB heterodimer is assembled mainly through the 
interaction of the two subunits at the C-terminal tail forming a coiled-coil domain. Although 
there is evidence that other parts of the two receptor subunits can interact with each other, it 
has been shown that the formation of the coiled-coil domain is crucial for GABAB receptor 
surface trafficking. In the absence of the GABAB(2) subunit the GABAB(1) does not reach the 
cell surface but remains in the endoplasmatic reticulum because of the amino acid sequence of 
four amino acids (RSRR) known as the retention signal at its cytoplasmic tail (Margeta-
Mitrovic et al. 2000; Pagano et al. 2001). In the presence of the GABAB(2) receptor subunit, 
by the formation of the coiled-coil domain, the retention signal of the GABAB(1) is masked 
and the receptor is successfully expressed at the cell surface (Couve et al. 1998). GABAB(2), 
however, does not need the co-expression of the GABAB(1) subunit to reach the cell surface. 
Moreover, it has been shown that there is an allosteric interaction between the VFTMs of both 
subunits, which results in a higher affinity of agonists for the VFTM of GABAB(1). This is an 
explanation for the lower affinity for agonist binding when only the GABAB(1) subunit was 
cloned in 1997 (see Kaupmann et al. 1997 or Bettler et al. 2004 for a review). Finally, the 
coupling of the GABAB receptor to its effector systems happens exclusively via the GABAB(2) 
receptor subunit. Namely, it is the intracellular loop 2 (i2) of the GABAB(2) that is crucial for 
G-protein coupling (Margeta-Mitrovic et al. 2001; Robbins et al. 2001; Havlickova et al. 
2002; Grünewald et al. 2003; Thuault et al. 2004; Duthey et al. 2002). This ”sideways” signal 
 26 
 
 
 
 
transduction from GABAB(1) subunit, that binds orthosteric ligands, to GABAB(2) subunits, 
that couples to the effector systems, is a unique feature of the GABAB receptor. 
 
4.2.2. The anatomical expression pattern of the GABAB receptor 
The GABAB receptor is abundantly expressed in the mammalian CNS. It has been found that 
GABAB binding sites are present in almost all neuronal populations (Bischoff et al. 1999), as 
well as in glial cells (Hosli et al. 1990; Oka et al. 2006), with the highest expression levels in 
the thalamic nuclei, the molecular layer of the cerebellum, the cerebral cortex, the 
interpeduncular nucleus and the dorsal horn of the spinal cord (Bowery et al. 1987; 
Kaupmann et al. 1997; Bischoff et al. 1999; Fritschy et al. 1999; Charles et al. 2001; Chu et 
al. 1990; Liang et al. 2000). 
Functional GABAB receptors are not only confined to the CNS. They are also expressed in 
peripheral tissues, for example heart, spleen, lung, liver, small intestine, large intestine, 
kidney, stomach, adrenal gland, testis, ovary and urinary bladder (see Bettler et al. 2004 for a 
review). 
 
4.2.3. The GABAB receptor and its effector systems 
The GABAB receptors are coupled to many different effector systems. They mostly couple to 
the Gαi and Gαo proteins (Asano and Ogasawara 1986; Morishita et al. 1990; Campbell et al. 
1993; Menon-Johansson et al. 1993; Greif et al. 2000).This mainly results in an inhibition of 
the adenylyl cyclase activity, as has been shown for many native experimental setups in vitro 
(Wojcik and Neff 1984; Cunningham and Enna 1996; Knight and Bowery 1996; Olianas et al. 
2005) and in vivo (Hashimoto and Kuriyama 1997; Gjoni et al. 2006), as well as in 
recombinant systems in vitro (Wise et al. 1999; Hirst et al. 2003; Urwyler, Gjoni et al. 2005). 
However, there are also reports of GABAB-mediated stimulation of adenylyl cyclase activity 
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in conjunction with activation of noradrenalin, pituitary adenylate cyclase activating protein 
(PACAP) or corticotrophin-releasing hormone (CRH) receptors in native preparations. These 
effects are most likely a result of a receptor-receptor crosstalk and have been postulated to 
involve the Gβγ subunits released upon GABAB receptor activation, which stimulate certain 
types of adenylyl cyclase in the presence of Gαs that originated from Gs coupled-GPCR 
activation  (Cunningham and Enna 1996; Knight and Bowery 1996; Olianas and Onali 1999; 
Onali and Olianas 2001). 
The function of GABAB receptors in the CNS mainly depends on their pre- or post-synaptic 
localization (Figure 8). When expressed presynaptically, they act as either autoreceptors or 
heteroreceptors, inhibiting the release of GABA or other neurotransmitters,  e.g. glutamate, 
various neuropeptides, catecholamines, serotonin or acetylcholine, into the synaptic cleft 
(Bowery et al. 1980; Taniyama et al. 1992; Waldmeier et al. 1994; Teoh et al. 1996; Bonanno 
et al. 1998; Bonanno et al. 1999). These effects are mainly mediated via the inhibition of the 
high-voltage activated calcium channels of the N-type or P/Q type which are both expressed 
in presynaptic terminals and shown to trigger neurotransmitter release (Takahashi et al. 1998). 
There is also evidence of interaction between presynaptically expressed GABAB receptors and 
L-type and T-type Ca2+ channels (for review see Bettler et al. 2004). Postsynaptic GABAB 
receptors, on the other hand, activate inwardly rectifying potassium channels (GIRK or Kir3) 
resulting in a prolongation of the slow inhibitory postsynaptic current (also known as late 
IPSC). This regulation involves Gβγ signaling (Lüscher et al. 1997). 
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Figure 8. Presynaptic and postsynaptic localization of the GABAB receptor in the CNS. Presynaptic 
autoreceptors (regulating the release of GABA) and heteroreceptors (regulating the release of other 
neurotransmitters, in this case glutamate) mediate their effect by inhibiting the influx of Ca2+ into the 
presynaptic terminals. Postsynaptically expressed GABAB receptors induce hyperpolarization of the 
postsynaptic terminal (late IPSC) by activating Kir3 channels. From (Cryan and Kaupmann 2005), 
with permission from Elsevier. 
 
4.2.4. The potential role of GABAB receptors in disease 
The GABAB receptor has been implicated in many neurological disorders, namely spasticity, 
pain, drug addiction, anxiety and depression, absence epilepsy and cognition (see Vacher and 
Bettler 2003; Bettler et al. 2004; Ong and Kerr 2005; Bowery 2006 for reviews). The 
widespread peripheral expression in mammalian organisms (see Subsection 4.2.2.) points to 
intestinal, pulmonary and bladder dysfunction as possible therapeutic applications for GABAB 
drugs. Insights in the potential role of the GABAB receptor in diseases were mostly obtained 
from experiments performed with baclofen and recently with GABAB knock-out mice 
(Schuler et al. 2001; Prosser et al. 2001). 
The selective GABAB receptor agonist baclofen is a lipophilic brain-penetrable derivative of 
GABA with central muscle-relaxant properties. It was synthesized in 1962 and has been in 
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clinical use in its racemic form under the trade name Lioresal since 1972 as a drug of choice 
for treating spinal spasticity and skeletal muscle rigidity, associated with cerebral palsy, 
multiple sclerosis, stiff-man syndrome and tetanus (Bowery 1993), even though its 
mechanism of action was unclear at the time of its release. The anti-spastic effects of baclofen 
are most likely mediated by the activation of the presynaptic GABAB receptors in the spinal 
cord, which inhibit the release of excitatory neurotransmitters onto the motoneurons in the 
monosynaptic reflex arc, resulting in relaxation of the contracted muscles. Additionally, 
baclofen has also been used in the treatment of chronic pain, e.g. neuropathic pain (see 
Fromm 1994 or Vacher and Bettler 2003; Bowery 2006; Bettler et al. 2004; Ong and Kerr 
2005 for reviews). The mechanism underlying GABAB-mediated antinociceptive effects is 
mediated via both the spinal cord (Malan et al. 2002) and higher brain centers (Ipponi et al. 
1999; Jasmin et al. 2003). 
A growing preclinical and clinical literature implicates the GABAB receptors in drug 
addiction. GABAB agonists were found to promote abstinence and reduce the use of cocaine, 
heroin, alcohol and nicotine (reviewed in Cousins et al. 2002) by modulating the mesolimbic 
dopamine system, also known as the reward and reinforcement circuitry (Robbins and Everitt 
1999). Efficiency of GABAB agonists to diminish cocaine self-administration and 
reinforcement has been observed in rats (Roberts et al. 1996; Roberts and Andrews 1997; 
Brebner et al. 1999, 2000 and 2002; Shoaib et al. 1998; Campbell et al. 1999) and clinical 
studies demonstrated effectiveness of baclofen in reducing cocaine craving in cocaine addicts 
(Ling and Shoptaw 1998; Shoptaw et al. 2003; Kaplan et al. 2004). Further, baclofen has not 
only been found to reduce self-administration of alcohol in rats (Colombo et al. 2002 and 
2004), but it was also found to be palliative against alcohol withdrawal and craving in humans 
patients, albeit in high doses (Ameisen 2005; Bucknam 2007; Addolorato et al. 2002a 
and.2002b). GABAB receptor activation has also been found to block the locomotor 
stimulatory effect of amphetamine and reduce its self-administration in animals (Bartoletti et 
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al. 2004; Brebner et al. 2005). Decrease in the self-administration of heroin (Xi and Stein 
1999; Di Ciano and Everitt 2003) and nicotine (Paterson et al. 2004a and 2004b) were also 
demonstrated upon administration of baclofen and the GABAB agonist CGP44532 in rats. 
Moreover, a significant association between variants of the human GABAB(2) gene and 
nicotine dependence has been reported that is thought to play a crucial role in the etiology of 
nicotine addiction (Beuten et al. 2005). 
GABAergic neurotransmission has been implicated in several psychiatric and emotional 
disorders, including anxiety and depression (Cryan and Kaupmann 2005). The involvement of 
the GABAB receptor in depression was first suggested by (Lloyd et al. 1985). Later, GABAB 
receptor antagonists were demonstrated to be effective in animal models for depression 
(Nakagawa et al. 1999; Slattery et al. 2005a), which could be linked with the finding that 
GABAB antagonists produced a rapid increase in the neurotrophins nerve growth factor 
(NGF) and brain-derived neurotrophic factor (BDNF) (Heese et al. 2000; Froestl et al. 2004). 
The anti-depressant effects of GABAB antagonists are in line with the findings that the genetic 
deletion of either GABAB(1) or GABAB(2) subunits in mice resulted in their antidepressant-like 
behavior in the forced swim test (FST), a model for the assessing of antidepressant action of 
drugs (Mombereau et al. 2004 and 2005). 
 Baclofen was demonstrated effective in panic disorders in human patients (Breslow et al. 
1989), which is in alignment with the fact that GABAB(1)-deficient mice display a more 
anxious phenotype than the WT animals (Mombereau et al. 2004). In addition, anxiolytic 
effects of baclofen were also shown in several animal models (see Cryan and Kaupmann 2005 
for a review). 
GABAB receptors appear to play a role in absence epilepsy, which is thought to be related to a 
predominance of inhibitory activity in the reticular thalamic nucleus, a part of the 
thalamocortical circuit responsible for development of seizures, that comprises mainly 
GABA-containing neurons (see Manning et al. 2003 for a review). Namely, GABAB receptor 
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antagonists inhibited spike and wave discharges in genetically modified animals, that are used 
as animal models for absence epilepsy, while administration of R(-)-baclofen aggravated the 
spontaneous seizures (Marescaux et al. 1992; Hosford et al. 1992). In addition, bilateral 
injections of R(-)-baclofen into specific relay nuclei and reticular nuclei of the thalamus 
increased spike and wave discharges in a concentration dependent fashion in rats with 
spontaneous absence seizures (Liu et al. 1992). Although this seems to be in contradiction 
with the fact that mice lacking functional GABAB receptors were more prone to spontaneous 
seizures (Schuler et al. 2001; Prosser et al. 2001), it must be noted that GABAB(1)-deficient 
mice suffer from a different type of absence seizures than observed in genetic animal models 
of absence epilepsy (see Bettler et al. 2004 for a review). 
Further, GABAB receptor antagonism has also been shown to improve spatial memory (Helm 
et al. 2005). The cognitive enhancer SGS742 is the first GABAB antagonist in clinical trials 
(Froestl et al. 2004). 
Peripherally, baclofen inhibited lower esophageal sphincter relaxation in dogs (Lehmann et al. 
1999), healthy humans (Lidums et al. 2000) and esophageal reflux disease patients (Zhang et 
al. 2002). 
Despite these numerous implications of the GABAB receptor in neurological and non-
neurological disorders, the only drug on the market that targets the GABAB receptor is 
baclofen. Its main shortcomings are deleterious side-effects such as sedation, motor 
impairment, hypothermia and fast onset of tolerance, observed in several animal models 
(Wang et al. 2002; Cryan et al. 2004; Lobina et al. 2005; Jacobson and Cryan 2005), as well 
as in human patients (Fromm 1994; Loubser and Akman 1996), which limit its widespread 
utility in preclinical and clinical settings. This is the main reason for the interest the discovery 
of positive allosteric modulators of the GABAB receptors CGP7930 and GS39783 arose 
within the scientific community (see Subsection 4.2.6.). 
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4.2.5. GABAB receptor desensitization 
The phenomenon of receptor desensitization plays an important physiological role acting as 
the feedback mechanism limiting both acute and lasting (chronic) overstimulation of GPCR 
signaling cascades. Desensitization of GPCRs has been extensively explored. There seems to 
be a “universal” mechanism by which most GPCRs desensitize. This “canonical” pathway 
mainly involves agonist-induced receptor phosphorylation of serine/threonine residues 
(usually in the i3 and/or the C-terminus) by intracellular kinases, usually GPCR kinases 
(GRKs). Phosphorylation is followed by the recruitment of cytoplasmic accessory proteins 
such as β-arrestins, which sterically hinder further coupling of the receptor to the G-protein 
thus acting as a turn-off switch of the signal. Subsequently most GPCRs internalize into 
clathrin-coated vesicles. Once internalized, receptors are targeted to specialized compartments 
where they are either dephosphorylated and recycled back to the plasma membrane 
(resensitization) or targeted to lysosomes for degradation (see Ferguson 2001; Tsao et al. 
2001; Clark and Rich 2003; Gainetdinov et al. 2004 for reviews). 
Desensitization of the GABAB receptor has been studied for a long time. It has been observed 
in in vivo studies in which chronic baclofen treatments resulted in the loss of its 
antinociceptive effects (Malcangio et al. 1992), the absence of GABAB-mediated induction of 
late IPSCs (Malcangio et al. 1995) and the loss of baclofen-induced hypothermic effects in 
rats (Lehmann et al. 2003). Although early in vitro studies have implicated phosphorylation 
by protein kinase C (PKC) (Taniyama et al. 1992) and protein kinase A (PKA) (Yoshimura et 
al. 1995) as a key step in GABAB receptor desensitization, several lines of evidence suggest 
that the GABAB receptor does not follow the β-arrestin-mediated desensitization pathway 
described above. Couve et al. (2002) have shown that the PKA-mediated phosphorylation of a 
single serine residue (Ser892) in the cytoplasmic tail of the GABAB(2) subunit enhanced the 
stability of the receptor at the cell surface. GABAB agonists thus reduced PKA activity, by 
 33 
 
 
 
 
inhibiting cAMP formation, resulting in a lesser degree of phosphorylation, thereby leading to 
desensitization of the receptor. Soon afterwards another study proposing an atypical 
mechanism of receptor desensitization came out, in which GRK4 was implicated as crucial 
for GABAB receptor desensitization in cerebellar granule cells (Perroy et al. 2003). 
Surprisingly, GRK4-mediated desensitization was found to be phosphorylation-independent, 
as it was promoted even in the absence of agonist-induced phosphorylation as well as by a 
mutant GRK4 lacking its kinase domain. Another report recently linked both GRK4 and 
GRK5 to GABAB receptor desensitization (Kanaide et al. 2006). However, this process is 
probably not generalized as GRK4 is absent from many brain regions that express high level 
of the GABAB receptor such as the cerebral cortex or the hippocampus (Sallese et al. 2000). 
Fairfax et al. (2004) provided evidence for endocytosis-independent degradation of the 
receptor at the cell surface as a mechanism of GABAB receptor desensitization (there was no 
proof of internal receptor pools, but the decrease in the cell surface receptor number was 
evident). Receptor degradation was found to correlate with a reduced phosphorylation at the 
Ser892 residue of the GABAB(2) receptor subunit, which is in alliance with the previously 
mentioned finding by Couve et al. (2002). In a recent report by Pontier et al. (2006) the 
phosphorylation by PKC was found to induce GABAB receptor desensitization, the pre-
association of the NEM sensitive fusion protein (NSF) with the GABAB receptor being a 
critical step in its phosphorylation by PKC. Further mechanisms that were proposed for 
GABAB receptor desensitization comprise regulation of  receptor-G-protein coupling by 
endogenous regulators of G-protein signaling (RGS) proteins (Mutneja et al. 2005) and 
agonist-induced endocytosis (Gonzales-Maeso et al. 2003; Laffray et al. 2007). Interestingly, 
Grampp et al. (2007) recently observed a high constitutive clathrin-mediated internalization 
of the receptor, which was not altered in the lasting presence of GABAB agonists/antagonists. 
Apparent divergences among findings in abovementioned studies might be due to different 
experimental systems employed to study receptor desensitization. It is possible that varying 
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expression levels of intracellular regulatory proteins, which serve as parts of the 
“desensitization machinery”, give rise to different desensitization pathways in different 
cellular contexts (see Chapter 5, Section 5.3. for further discussion). 
 
4.2.6. Positive allosteric modulators of the GABAB receptor 
The development of functional and cell-based assays represents an important progress in 
discovery of GPCR drugs. In contrast to radioligand binding experiments, which are based on 
the displacement of a known (orthosteric) labeled ligand, the use of functional assays in high 
throughput screening (HTS) facilitates the identification of compounds with different 
mechanisms of activation, e.g. allosteric modulators (Rees et al. 2002; Christopoulos et al. 
2004). One functional assay, that is frequently used to measure GPCR function, is agonist-
promoted GTP(γ)35S binding in cell membrane preparations. This experimental system 
measures the first step in the signaling cascade of a GPCR (Hilf et al. 1989; Harrison and 
Traynor 2003). As a result of a GTP(γ)35S screen in membranes of a recombinant Chinese 
hamster ovary (CHO) cell line stably expressing the GABAB heterodimer the two positive 
allosteric modulators CGP7930 and GS39783 came out (Urwyler et al. 2001 and 2003). These 
two compounds are structurally different, but they exerted similar actions with similar 
potencies (in the low micromolar range) on both native and recombinant receptors. Without 
effects on their own in the absence of agonists, CGP7930 and GS39783 increased not only the 
potencies of the GABAB agonists GABA and R(-)-baclofen in the GTP(γ)35S assay system, 
but also their maximal efficacies (Urwyler et al. 2001 and 2003). Together with allosteric 
enhancers of the mGluR1 receptor (Knoflach et al. 2001), CGP7930 was the first example of 
a compound with a dual mechanism of action (an effect on both agonist potency and the 
maximal effect, as predicted by the allosteric two-state model of receptor activation, see 
Subsection 4.1.2.). For example, benzodiazepines, possibly the best-described class of 
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positive allosteric modulators, act only by increasing the potency of GABAA agonists, without 
influencing their maximal effects. The dual mode of action of CGP7930, an enhancement of 
both the potencies and the maximal effects of the agonists GABA, APPA and the active R(-) 
enantiomer of baclofen in the GTP(γ)35S assay in membranes from human cortex, was 
confirmed by others (Olianas et al. 2005). 
An increase of agonist affinity by CGP7930 and GS39783 also became apparent in 
radioligand binding experiments. A saturation experiment with the selective GABAB agonist 
[3H]-APPA in the presence of CGP7930 revealed an increase in affinity, without a change in 
the Bmax value (Urwyler et al. 2001). Radioligand kinetic experiments in rat brain cortex 
membranes, examining the rates of association and dissociation of [3H]-APPA, in the 
presence of GS39783 have yielded surprising results. The rate of association of the 
radioligand in the presence of GS39783 was lower than in its absence. However, this effect  
was overcompensated by an even greater effect on slowing down the dissociation, resulting in 
a net increase of affinity (Urwyler et al. 2003). An increase in agonist affinity was also 
observed in displacement experiments. The curves describing the displacement of the 
radiolabeled GABAB antagonist CGP62349 from rat brain membranes by GABA were fitted 
better when a two-site model was used, rather than a one-site model (Figure 9). The two states 
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Figure 9. Effects of CGP7930 on the displacement of the GABAB antagonist [3H]-CGP62349 by 
GABA from native GABAB receptors in rat cortical membranes. Filled circles: control curve with 
GABA alone, open squares: concentration-response curve of GABA in the presence of 30 µM 
CGP7930. Adapted from (Urwyler, Gjoni et al. 2004), with permission from Elsevier. 
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correspond to the receptor being either coupled or uncoupled from its G-protein which results 
in different affinities for the two states (Hill et al. 1984; Parmentier et al. 2002). The positive 
allosteric modulators CGP7930 and GS39783 increased the affinities for both receptor states 
(Urwyler et al. 2001 and 2003). Moreover, the proportion of receptors in the high affinity 
state was increased in their presence, suggesting that CGP7930 and GS39783 also promoted 
the coupling of the receptor to G-proteins. 
Concerning other in vitro experimental setups, increases of GABA effects by CGP7930 and 
GS39783 were also seen measuring the activation of Kir3 channels co-transfected in Xenopus 
laevis oocytes together with the GABAB receptor. No potassium currents were elicited in the 
presence of either modulator in the absence of GABA (Urwyler et al. 2001 and 2003). 
Further, the modulators were found to increase the potency and the maximal effects of 
agonists to inhibit 7β-forskolin-induced cAMP production, only with marginal effects on their 
own (Onali et al. 2003; Olianas et al. 2005; Urwyler, Gjoni et al. 2005). CGP7930 also 
increased the potencies and the maximal efficacies of R(-)-baclofen or GABA to stimulate 
either basal or CRH-stimulated cAMP production in the membranes of rat frontal cortex and 
the granule cell layer of rat olfactory bulb (Onali et al. 2003). This effect is likely mediated 
via the stimulatory action of βγ subunits of the Gi/Go proteins on adenylyl cyclase type II and 
IV (see Tang and Gilman 1992 for a minireview). Moreover, in a more physiological setting 
(Chen et al. 2005) have observed effects of CGP7930 on baclofen-induced depression of the 
spontaneous activity in dopamine (DA) cells of the ventral tegmental area (VTA) in rat brain 
slices, which probably occurs via the activation of Kir3 channels. CGP7930 increased the 
potency of baclofen to inhibit the spontaneous spiking. Since baclofen fully blocked the firing 
of DA neurons in the VTA at its highest concentrations, no further enhancement of its 
maximal effect was observed in the presence of CGP7930. This kind of a ceiling effect was 
also present when GABAB-mediated inhibition of calcium fluctuations was measured in 
neuronal cortical cultures (Urwyler et al. 2001). 
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To summarize, the in vitro studies mentioned above have found positive allosteric modulators 
of the GABAB receptor CGP7930 and GS39783 to increase both the affinities and the 
efficacies of agonists, without having a significant effect on their own in their absence. On the 
other hand, there was one study by (Binet et al. 2004), in which the binding site of CGP7930 
was identified to lay in 7TM of GABAB(2), that showed a direct activation of the receptor by 
CGP7930 in a manner of a partial agonist. It must be noted that a very sensitive system was 
used in this study, seemingly with a high degree of receptor reserve, which is most likely the 
reason why the low efficacy partial agonism of CGP7930 alone was detected. Another 
mapping study by (Dupuis et al. 2006) discovered that the binding site for GS39783 was also 
located in the 7TM of GABAB(2). 
 
So far there has only been one study, that is a part of this thesis (Chapter 5, Section 5.4.), in 
which the principles of allosteric modulation of the GABAB receptor were shown on a 
biochemical level in vivo (Gjoni et al. 2006). In vivo microdialysis in the rat striatum was 
employed to measure cAMP, the second messenger of GABAB receptor activation, the results 
of which strongly suggested an allosteric mechanism of action of GS39783 in vivo (see 
Chapter 5, Section 5.4. or Gjoni et al. 2006). 
On the other hand, behavioral effects of CGP7930 and GS39783 have been extensively 
studied in animal models. CGP7930 synergistically increased the sedative/hypnotic effects of 
baclofen and γ-hydroxybutiric acid (GHB) in mice, without having an effect on its own (Carai 
et al. 2004), which again supports the notion of an allosteric enhancement. GS39738 was 
found to have anxiolytic properties when tested in the classical behavioral paradigms, for 
example in the elevated zero maze or the light-dark box (Cryan et al. 2004; Mombereau et al. 
2004). However, it had no antidepressant action in the forced swim test (Cryan et al. 2004; 
Slattery et al. 2005a). Importantly, GS39783 lacked all baclofen- and benzodiazepine-related 
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side-effects, namely sedation, hypothermia, muscle relaxation, cognitive impairment, 
impairment of motor abilities and the potentiation of ethanol effects (Cryan et al. 2004).  
Because the implications of GABAB receptors in drug addiction have been extensively 
studied (see Subsection 4.2.4.), effects of the positive allosteric modulators CGP7930 and 
GS39783 have also been assessed in animal models of drug abuse. Smith et al. (2004) 
demonstrated that CGP7930 and GS39783 decreased cocaine-self administration in rats, with 
no evidence of inducing sedation or motor ataxia. In addition, Slattery et al. (2005b) showed 
that GS39783 attenuated the reward-facilitating effects of cocaine by using intracranial self-
stimulation procedure in rats. GS39783 attenuated chronic cocaine-induced locomotor 
sensitization in mice, without affecting the basal locomotor activity. It also blunted ∆FosB 
upregulation in dorsal striatum and blocked the upregulation and activation of dopamine- and 
cAMP-regulated phosphoprotein of 32kDa (DARPP-32) and cAMP-response-element-
binding protein (CREB), all associated to chronic cocaine (Lhuillier et al. 2006). Similarly, 
GS39783 reduced the nicotine-induced accumulation of ∆FosB in rat dorsal striatum 
(Mombereau et al. 2007). Decreases of ethanol-intake mediated CGP7930 and GS39783 in 
rats have also been reported (Orru et al. 2005; Liang et al. 2006). 
In conclusion, although it is difficult to definitely confirm allosteric mechanisms in vivo, the 
findings outlined above indicate that CGP7930 and GS39783 act via similar mechanisms as 
they do in vitro. The positive allosteric modulators of the GABAB receptor mimic/potentiate 
the effects of baclofen in behavioral animal models, but lack the severe side-effects of 
baclofen, which makes them valuable tools in GABAB receptor research. 
   
Other members of the family 3 GPCR, namely the CaSR and certain mGluRs, have been 
shown to be either directly activated or modulated by extracellular calcium, respectively 
(Kubo et al. 1998; Saunders et al. 1998). GABAB receptor function was also demonstrated to 
be susceptible to Ca2+ ions in two independent studies (Wise et al. 1999; Galvez et al. 2000b). 
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Sensitivity to a regulation by Ca2+-ions was observed in both native and recombinant GABAB 
receptors. In the GTP(γ)35S assay system, Ca2+ increased the potency, but not the maximal 
effect of GABA. Similar observations originated from other experimental systems, such as 
potassium channel regulation in Xenopus oocytes, measurement of IP turnover (via artificial 
coupling to the PLC pathway) or inhibition of forskolin-amplified adenylyl cyclase activity 
(cAMP). In all the experimental systems, apart from cAMP, baclofen was insensitive to the 
potentiation mediated by Ca2+ ions. Point mutation experiments have identified the Ser269 
residue on the GABAB(1), which lies in the close vicinity of the orthosteric ligand binding site 
(Galvez et al. 1999; Bernard et al. 2001), as being responsible for the effects of Ca2+ ions on 
GABAB receptor function (Galvez et al. 2000b). If a true allosteric mechanism underlies the 
effects of calcium ions on GABAB receptor function, the presence of Ca2+ should change the 
conformation of the receptor protein, possibly to optimize the binding of GABA in the 
binding pocket (see Galvez et al. 2000b for further discussion). Alternatively, it has been 
proposed that Ca2+ acts as a chelator of the carboxylic group of GABA and residues of Ser269 
and Tyr366 (Costantino et al. 2001). Whereas this alternative hypothesis provides an 
explanation for the insensitivity of baclofen to modulation by Ca2+, it is difficult to distinguish 
the two mechanisms experimentally. The facts that the EC50 of calcium, that is responsible for 
its enhancing actions, lies in the low micromolar range (37 µM) (Galvez et al. 2000b) and the 
concentrations of calcium in the cerebrospinal fluid being in the milimolar range, make it 
unclear whether calcium-mediated modulation of GABAB receptor function is of any 
physiological relevance, as in normal conditions the calcium site in the GABAB binding 
pocket is most likely saturated. However, under pathophysiological conditions such as 
epileptic seizures or ischemia, synaptic calcium concentrations might drop significantly 
(Pumain et al. 1983; Heinemann et al. 1986; Lazarewicz 1996). 
Arylalkylamine-like compounds and certain L-amino acids and dipeptides, which are known 
to allosterically modulate the CaSR (Hammerland et al. 1998; Nemeth et al. 1998; Conigrave 
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et al. 2000) have also been claimed to be positive allosteric enhancers of GABAB receptors 
(Kerr et al. 2002; Kerr and Ong 2003). Electrophysiological recordings in brain slices were 
used to demonstrate their action. The abovementioned compounds increased the potency and 
the maximal effect of baclofen to induce field potentials, without inducing field potentials by 
themselves when applied alone. However, in such an electrophysiological setup the enhancing 
effects of these compounds could well have been due to other mechanisms, not necessarily of 
allosteric nature, for example receptor-receptor cross-talk or downstream effects. Since we did 
not observe any effects of these compounds on the affinity or efficacy of GABA in various 
assay systems, more suitable for detecting true allosteric interactions (Urwyler, Gjoni et al. 
2004), it is unlikely that the mechanism of action of these compounds is of allosteric nature. 
The mechanism of action of these compounds, thus, remains unclear and more investigations 
are needed to answer that question. 
 
 
4.3. The questions addressed in this thesis 
During this PhD project, I have focused mostly on the positive allosteric modulators of 
GABAB receptors, evaluating their effects biochemically both in vitro and in vivo. 
Despite the comprehensive previous in vitro characterization of the positive allosteric 
modulators of GABAB receptors CGP7930 and GS39783, the effects these compounds exert 
upon ligands with different intrinsic properties (competitive antagonists and partial agonists) 
were not known. According to the theoretical models of receptor activation (see Subsection 
4.1.2.), all chemical species can be influenced by allosteric modulators. To address the 
question of the effects that positive allosteric modulators CGP7930 and GS39783 have on 
ligands other than agonists, I have examined both affinities and the efficacies of a number of 
GABAB receptor ligands and confirmed the theoretical predictions that antagonists and partial 
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agonists are also amenable to positive allosteric modulation. Moreover, CGP7930 and 
GS39783 have also been demonstrated to be excellent tools for elucidating the intrinsic 
properties of orthosteric ligands. See Chapter 5, Section 5.1. 
Secondly, as discussed in Section 4.1., allosteric modulators act only upon receptors 
stimulated by endogenous agonists and not upon the whole receptor population. This means 
that they affect the strength of the physiological signaling, while preserving the pattern of 
activation (e.g. patterns of neuronal signaling), unlike exogenous orthosteric agonists, which 
activate all their receptors, indiscriminately of the temporal and the spatial organization (see 
Figure 2). For this reason, one of the postulated advantages of allosteric over orthosteric 
ligands is that continuous activation involving positive allosteric modulation is less likely to 
induce receptor desensitization, compared to a lasting exposure to an orthosteric ligand. This 
assumption was tested in Chapter 5, Section 5.2. The approach used in this thesis was to 
continuously activate (both native and recombinant) GABAB receptors in vitro to the same 
extent, using either an orthosteric agonist or a combination of an orthosteric agonist and 
GS39783, and subsequently assess their functional responses and expression levels at the cell 
surface.  
Further, while studying GABAB receptor desensitization, surprising changes in behavior of 
ligands were observed in the recombinant cell line stably expressing the GABAB receptor 
upon receptor desensitization. A number of selective GABAB antagonists were found to have 
inverse agonistic efficacy, the partial agonist 2-OH-saclofen lost its efficacy and the positive 
modulator GS39783 now had an agonistic effect on its own. Nothing similar has been 
observed for the GABAB receptor so far, but there are a few reports on the µ-, δ- and κ-opioid 
and β2-adrenergic receptors describing similar phenomena. See Chapter 5, Section 5.3. 
Finally, effects of positive allosteric GABAB receptor modulators have been extensively 
studied in behavioral models (see Subsection 4.2.6.). While they were effective in, for 
example, many anxiety paradigms, the positive allosteric modulators were devoid of side-
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effects that are usually displayed by baclofen, such as sedation, muscle relaxation or 
locomotor impairment. Although, this is compatible with an allosteric enhancement, there 
were no studies demonstrating the allosteric mechanism of action in vivo. The final part of 
this thesis describes in vivo microdialysis experiments in rat striatum, measuring the second 
messenger cAMP as an assessment of GABAB receptor activation. It demonstrates that the 
effects of the positive allosteric modulator GS39783 on the GABAB receptor in vivo is similar 
to the one observed in vitro, strongly suggesting an allosteric mechanism of action in living 
animals (Chapter 5, Section 5.4.). 
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5. Results and discussions 
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5.1. Mechanisms of allosteric modulation at GABAB receptors by CGP7930 
and GS39783: effects on affinities and efficacies of orthosteric ligands with 
distinct intrinsic properties 
 
S.Urwyler, T.Gjoni, J.Koljatić and D.S. Dupuis 
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Published in Neuropharmacology 48 (2005) 343-353, republished in this thesis with 
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All data in this study, except for the GTP(γ)35S assay, were produced by T. Gjoni 
(GTP(γ)35S was performed by scientific associates D.Monna and M. Horvath) 
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5.1.1. Abstract 
We determined the effects of the allosteric γ-aminobutyric acid B receptor modulators 
CGP7930 and GS39783 on binding and function of orthosteric ligands with distinct intrinsic 
properties. In radioligand binding (saturation or displacement) experiments, the affinities of a 
number of competitive antagonists were decreased by the modulators, with no change in 
receptor number. The binding curves of the partial agonist CGP47656 comprised a high and a 
low affinity component; the affinity of the former was increased by the allosteric agents. The 
maximal stimulation of GTP(γ)35S binding via recombinant GABAB receptors by CGP47656 
was increased 4-fold in the presence of 30 µM CGP7930 or GS39783. Two compounds 
known so far as “silent” competitive GABAB receptor antagonists, CGP35348 and 2-OH-
saclofen, did not stimulate GTP(γ)35S binding on their own, but became low efficacy partial 
agonists in the presence of the two modulators. The potency of GABA to inhibit the formation 
of cAMP induced by a forskolin analog in a recombinant CHO cell line expressing GABAB 
receptors was increased by the modulators. CGP35348 and 2-OH-saclofen, like CGP47656, 
were partial agonists on their own in this assay, and the allosteric modulators increased the 
potency as well as the efficacy of all three compounds. With CGP52432, there was a trend 
toward inverse agonism in the cAMP assay. These results show that the intrinsic properties of 
orthosteric ligands are highly dependent on the characteristics of the assay system used and 
that allosteric modulators are useful tools for elucidating these properties.  
 
Keywords: CGP7930; GS39783; GABAB receptor; Allosteric modulation; Affinity; Efficacy  
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Abbreviations: cAMP, cyclic 3',5'-adenosine-monophosphate; CHO, Chinese hamster ovary; 
7β-forskolin, 7-deacetyl-7-(O-N-methylpiperazino)-γ-butyryl-forskolin, dihydrochloride; 
GABA, γ-aminobutyric acid; GPCR, G-protein-coupled receptor; GTP(γ)S, guanosine 5'-O-
(3-thiotriphosphate); IBMX, isobutyl-methylxanthine; mGluR, metabotropic glutamate 
receptor; RIA, radioimmunoassay; SPA, scintillation proximity assay; TCM, ternary complex 
model; VFTM, Venus flytrap module; WGA, wheat germ agglutinin 
 
5.1.2. Introduction 
Allosteric modulators are molecules that bind to a site on a neurotransmitter or hormone 
receptor which is topographically distinct from the orthosteric binding pocket for agonists or 
competitive antagonists. Allosteric agents usually have little or no intrinsic agonistic activity 
of their own, but induce conformational changes in the receptor protein which affect its 
interaction with orthosteric ligands. The therapeutically widely used benzodiazepines are 
well-known examples of such drugs. They enhance the sensitivity of the ionotropic inhibitory 
GABAA receptor without stimulating it directly themselves and without affecting the 
magnitude of the maximal response. A number of allosteric enhancers are also known for G 
protein - coupled receptors (GPCRs) (for reviews see Christopoulos 2002; Christopoulos and 
Kenakin 2002; Jensen and Spalding 2004). Interestingly, several examples of allosteric drugs 
which not only enhance the potency, but also the intrinsic efficacy of agonists at GPCRs have 
been recently described for GABAB (Urwyler et al. 2001 and 2003), metabotropic glutamate 
mGluR1 (Knoflach et al. 2001), mGluR2 (Schaffhauser et al. 2003) and mGluR4 (Maj et al. 
2003; Mathiesen et al. 2003), as well as adenosine A3 receptors (Gao et al. 2002).  
Several theoretical receptor models describe various aspects of ligand binding and receptor 
activation. The two state - model (reviewed by Leff 1995; Fig. 3 in Chapter 4) asserts that a 
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receptor exists in two interconvertible conformations, a resting (R) and an activated (R*) state. 
The spontaneous formation of R* without agonist binding is the basis for constitutive receptor 
activity. The binding of an agonist stabilizes the activated form R* (α > 1), whereas an inverse 
agonist preferentially binds to and shifts the equilibrium to the resting state (α < 1). 
Competitive antagonists block the access of agonists to their binding site, but are themselves 
neutral in terms of receptor activation (α = 1). This model thus accounts for intrinsic 
efficacies (α) of orthosteric ligands, but does not allow understanding the effects of allosteric 
drugs. Changes in the binding affinity of orthosteric ligands induced by allosteric agents have 
traditionally been described by a ternary complex model (TCM) (Fig. 4 in Chapter 4), which 
was originally designed for the regulation of agonist binding by receptor - G-protein coupling 
(De Lean et al. 1980), but also encompasses mechanisms of reciprocal regulation of the 
binding of two low molecular weight compounds to distinct sites on the same receptor 
protein. However, this model does not take into account the degree of agonist-induced 
receptor activation. Although the “allosteric ternary complex model” (Lefkowitz et al. 1993) 
was a first attempt to combine the two previous  models, the newly observed phenomenon 
that allosteric modulators in some cases enhance both agonist affinity and efficacy (see 
above), is accommodated only by more recently developed theoretical concepts (Hall 2000; 
Christopoulos and Kenakin 2002). An extension of the two state model of receptor activation 
(Hall 2000; Fig. 5 in Chapter 4), introduces the allosteric constant δ, by which the intrinsic 
efficacy α of a ligand is modified. This model treats the allosteric interactions in purely 
numerical terms, i.e. the constants γ and δ are a priori independent of the qualitative 
(agonistic or antagonistic) nature (i.e., the values of α) of the orthosteric ligand. Therefore, 
antagonists or inverse agonists should be amenable as much as agonists to allosteric 
modulation. Recent concepts state that compounds devoid of any intrinsic activity (α exactly 
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equaling one) are likely to be rare, and that most compounds considered being “silent” 
competitive antagonists are in fact low efficacy partial agonists or inverse agonists 
 
 
Fig. 1. Chemical structures of the compounds tested and referred to in this study. Agonists: GABA, 
baclofen, APPA. Partial agonist: CGP47656. Allosteric modulators: CGP7930, GS39783. The other 
compounds shown are known from the literature (Bowery et al. 2002) as competitive antagonists, but 
some of them were found in this study to be partial (CGP35348, 2-OH-saclofen) or inverse 
(CGP52432) agonists. 
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(Strange 2002; Milligan 2003; Kenakin 2004). The detection of these properties is highly 
dependent on the assay system used. In this study, we have tested and confirmed these various 
predictions by examining the effects of the two GABAB receptor modulators CGP7930 and 
GS39783 (Urwyler et al. 2001 and 2003) on a number of well known orthosteric ligands 
(Bowery et al. 2002) with distinct intrinsic efficacies (Fig. 1). In particular, we show that 
allosteric modulators decrease the affinities of competitive antagonists and strongly increase 
the efficacies of partial agonists, thus revealing intrinsic activities of compounds previously 
believed to be “silent” antagonists. 
 
5.1.3. Materials and methods 
Radioligand binding experiments: The binding of [3H]-CGP62349 (85Ci/mMol, American 
Radiolabeled Chemicals Inc., St. Louis, MO) to rat cortical membranes was measured in the 
scintillation proximity assay (SPA) format as described previously (Urwyler et al. 2003). The 
assay mixture in a final volume of 250 µl contained 20 mM Tris-HCl buffer (pH 7.4), 118 
mM NaCl, 4.7 mM KCl, 1.8 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 5 mM D-glucose, 
1 nM [3H]-CGP62349 (or differing concentrations in saturation experiments), the test 
compounds at the desired concentrations, rat cortical membranes (ca. 15 µg protein), and 1.5 
mg wheat germ agglutinin (WGA) - coated SPA beads (Amersham Biosciences, Little 
Chalfont, Buckinghamshire, UK). Non-specific binding was assessed in the presence of 5 µM 
CGP56999. The samples were incubated for 90 min at room temperature, before being 
counted in a Wallac 1450 Microbeta liquid scintillation counter. Saturation and displacement 
curves were analyzed with nonlinear regression using Prism 3.0 (GraphPad software, San 
Diego, CA). 
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GTP(γ)35S assay: These experiments using membranes from Chinese hamster ovary (CHO) 
cells stably expressing GABAB receptors were also performed as described previously 
(Urwyler et al. 2001). The composition of the assay mixtures (in a final volume of 250µl in 
96-well clear-bottom microtiter plates [WALLAC IsoplatesTM]) was as follows: 50 mM Tris-
HCl buffer, pH 7.7; 10 mM MgCl2; 0.2 mM EGTA; 2 mM CaCl2; 100 mM NaCl; 10 µM 
guanosine 5‘-diphosphate (Sigma Chemical, Buchs, Switzerland), 50 µl of the membrane 
suspension (approximately 10-20 µg of protein), 1.5 mg WGA-coated SPA beads (Amersham 
Biosciences), 0.3 nM GTP(γ)35S (ca 1000 Ci/mmol, stabilized solution, Amersham 
Biosciences), and the test compounds at the appropriate concentrations. Non-specific binding 
was measured in the presence of unlabelled GTP(γ)S (10 µM, Sigma). The samples were 
incubated at room temperature for 60 min, before the SPA beads were sedimented by 
centrifugation at 2600 rpm for 10 min. The plates were then counted in a Wallac 1450 
Microbeta liquid scintillation counter. For data analysis, basal activity, measured in the 
absence of agonist, was subtracted from all the other values. The effects of test compounds 
were calculated relative to the stimulation above baseline obtained with a maximally active 
concentration (100µM) of GABA. Concentration - response curves were analyzed by non-
linear regression using GraphPad Prism 3.0. 
 
Adenylyl cyclase assays: A stable CHO cell line co-expressing human GABAB(1b) together 
with rat GABAB(2) (Urwyler et al. 2001) was used for these experiments. The cells were 
cultured in Dulbecco's modified eagle medium (DMEM, glutamine-free, Invitrogen, Basel, 
Switzerland) supplemented with 10% fetal calf serum, 20µg/ml L-proline, 500µM glutamine, 
1mg/ml geneticin, 250µg/ml zeocin. The cells were grown to 80-90 % confluency in 15 cm 
cell culture dishes. For the cyclic 3',5'-adenosine-monophosphate (cAMP) measurements, the 
cells were treated with DMEM supplemented with 1 mM 3-isobutyl-1-methylxanthine 
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(IBMX) (Fluka, Buchs, Switzerland) for 15 minutes at 37°C and 5% CO2. The cells were 
harvested by trypsinization, resuspended in Hepes buffer (Invitrogen) supplemented with 1 
mM IBMX and 2 mM CaCl2 and splitted into 96-well clear-bottom microtiter plates 
[WALLAC IsoplatesTM]) at a density of 15’000 – 30’000 cells per well. The cell suspension 
was then incubated for 20 minutes at 37oC in a total volume of  45µl with Hepes buffer 
containing IBMX (1 mM), CaCl2 (2 mM), the water-soluble forskolin analog 7-deacetyl-7-(O-
N-methylpiperazino)-γ-butyryl-forskolin dihydrochloride (7β-forskolin, Calbiochem, Juro 
Supply, Lucerne, Switzerland) (100µM), and  the test compounds at the concentrations given 
in the Subsection 5.1.4. The amount of cAMP formed was quantified by radioimmunoassay 
(RIA)  following the cAMP SPA Biotrak direct screening assay system protocol from  
Amersham Biosciences: At the end of the incubation period, 5µl of lysis reagent (containing 
dodecytrimethylammonium bromide [10%]) were added to each well. After 5 minutes of 
shaking, 150µl of immunoreagent solution (containing rabbit anti-succinyl cAMP serum, 
donkey anti-rabbit IgG second antibodies coated at the surface of SPA beads, and adenosine 
3',5'-cyclic phosphoric acid 2'-O-succinyl-3-[125I]iodotyrosine methyl ester as a tracer) were 
added to each sample. The plates were incubated at room temperature for 15-20 hours and 
then counted on a WALLAC 1450 microbeta Trilux scintillation counter. The quantification 
of the cAMP formed was performed with the aid of an appropriate RIA cAMP standard curve. 
 
Protein concentrations were measured with the Bradford assay method, using the Bio-Rad 
protein assay kit and bovine serum albumin as a standard. 
 
Chemicals: The sources of commercially obtained chemicals are given above. The GABAB 
receptor modulators GS39783 and CGP7930, as well as the orthosteric ligands tested in this 
study (Fig. 1) were all available in house. Stock solutions were usually prepared in DMSO 
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and subsequently diluted in the respective assay buffers. The final DMSO concentrations 
usually did not exceed 0.3% and did not interfere with the measured parameters. 
 
5.1.4. Results  
Saturation binding experiments with [3H]-CGP62349. The effects of the allosteric 
modulators CGP7930 and GS39783 in saturation binding experiments with [3H]-CGP62349 
are shown in Fig. 2. Both compounds slightly, but significantly and consistently, decreased 
the affinity of this antagonist radioligand for native GABAB receptors in rat cortical 
membranes. In fact, the Kd was significantly increased from 0.54 ± 0.04 nM (without 
modulator, mean ± SEM, N = 4) to 0.83 ± 0.04 nM (p < 0.05) or to 0.92 ± 0.11 nM (p < 0.01) 
in the presence of 30 µM CGP7930 or 30 µM GS39783, respectively. These Kd values were 
used accordingly for the conversion of IC50 values obtained in subsequent displacement 
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Fig. 2. Effects of allosteric modulators on the binding of the antagonist radioligand [3H]-
CGP62349 to native GABAB receptors in rat cortical membranes. Saturation curves were 
measured in the absence of modulators (filled squares) or in the presence of CGP7930 (30 µM, 
squares) or GS39783 (30 µM, circles). The mean Kd and Bmax-values from four such experiments are 
given in the text. 
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experiments into their corresponding Ki-values. On the other hand, Bmax-values for [3H]-
CGP62349 binding remained unchanged upon the addition of the two modulators (in 
pmol/mg protein: control 4.5 ± 0.4; with CGP7930: 4.4 ± 0.3; with GS39783: 4.6 ± 0.4). 
 
Effects of allosteric modulators on the displacement of [3H]-CGP62349 by orthosteric 
GABAB receptor ligands. Some representative curves illustrating the displacement of the 
antagonist radioligand [3H]-CGP62349 from native GABAB receptors in rat cortical 
membranes are shown in Fig. 3. 
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Fig. 3. Displacement of [3H]-CGP62349 from native GABAB receptors in rat cortical membranes 
by, from left to right, CGP54626 (open symbols, solid lines), CGP47656 (filled symbols, solid lines), 
SCH50911 (open symbols, dotted lines) and 2-OH-saclofen (filled symbols, dotted lines). Diamonds: 
control curves; triangles: curves measured in the presence of 30 µM GS39783; inverted triangles: 
curves with 30 µM CGP7930. The graph shows typical curves from a single experiment; a summary of 
the data from a number of such experiments is given in Table 1. 
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The curve fit parameters for all the compounds tested are given in Table 1. Best curve fits 
were obtained with a one-site model in all cases, with the exception of CGP47656. The 
displacement curves with this partial agonist were shallow (Fig. 3), consisting of a high 
affinity and a low affinity component (Table 1). The affinities of the high affinity, but not of 
the low affinity, sites were significantly increased by the allosteric modulators CGP7930 and 
GS39783 (Table 1). The relative proportion of high affinity sites was also increased, although 
this change did not quite reach statistical significance (ANOVA: p = 0.07). The inhibition 
 
Displacing 
ligand 
pKi control  
(-log M) Ki  
pKi with 30µM 
CGP7930 
(-log M) 
Ki  
pKi with 30µM 
GS39783 
(-log M) 
Ki  
CGP35348 5.11 ± 0.05 (6) 7.7 µM 5.18 ± 0.08 (6) 6.6 µM 5.20 ± 0.07 (6) 6.3 µM  
CGP47656 7.15 ± 0.05  
(44 ± 3.4 %) 
5.97 ± 0.12 (6) 
71 nM 
 
1.07 µM 
7.39 ± 0.10  * 
(54 ± 2.9 %) 
6.01 ± 0.18 (6) 
41 nM 
 
0.98 µM 
7.45 ± 0.10 * 
(53 ± 2.6 %) 
6.06 ± 0.10 (6) 
35n M 
 
0.87 µM 
CGP52432 7.25 ± 0.10 (4) 57 nM 7.09 ± 0.12 (4) * 81 nM 7.04 ± 0.08 (4) ** 91 nM 
CGP54626 8.44 ± 0.05 (4) 3.6 nM 8.39 ± 0.09 (4) 4.1 nM 8.23 ± 0.04 (4) * 5.9 nM 
CGP56999 9.60 ± 0.06 (4) 0.25 nM 9.37 ± 0.04 (3) * 0.43 nM 9.39 ± 0.03 (3) * 0.41 nM 
CGP62349 9.26 ± 0.05 (8) 0.55 nM 9.07 ± 0.05 (8) ** 0.85 nM 8.99 ± 0.06 (8) ** 1.02 nM 
2-OH-saclofen 4.62 ± 0.05 (8) 24 µM 4.66 ± 0.05 (8) 21.9 µM 4.70 ± 0.07 (8) 20 µM 
SCH50911 6.30 ± 0.08 (4) 0.5 µM 6.17 ± 0.09 (4) ** 0.68 µM 6.11 ± 0.11 (4) ** 0.78 µM 
 
 
Table 1. Effects of CGP7930 and GS39783 on the affinities of orthosteric ligands for native 
GABAB receptors from rat cortical membranes in radioligand binding assays. The binding of 
[3H]-CGP62349 to membranes from rat brain cortex was measured as described in the Subsection 
5.1.3. Inhibition curves with the ligands shown as displacers were constructed as illustrated in Fig. 3. 
Best curve fits were obtained with a one-site model in all cases, with the exception of CGP47656 (the 
relative proportion of high affinity sites is given in percent). The results shown are means ± SEM from 
(N) independent experiments. *: p<0.05, **: p<0.01 compared to the corresponding control values 
(ANOVA / Dunnett’s test).  
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curves of the other compounds, previously described as competitive GABAB receptor 
antagonists, seemed to be little affected or, in some cases, slightly shifted toward lower 
concentrations by the two allosteric modulators (Fig. 3). However, a precise calculation of the 
corresponding Ki-values, taking into account the modulator effects on the affinity of the 
radioligand (Cheng and Prusoff 1973), revealed a slight, but significant decrease in binding 
affinities for most orthosteric ligands (Table 1). The only noteworthy exceptions were 
CGP35348 and 2-OH-saclofen. The affinities of these two compounds were slightly, but not 
significantly, increased in the presence of the allosteric modulators. 
 
Effects on allosteric modulators on orthosteric ligands in GTP(γ)35S assays (experiments 
performed by scientific associates D. Monna and M. Horvath). The compound CGP47656 
stimulated GTP(γ)35S binding to recombinant GABAB receptors to maximally 25% of the 
maximal effect of GABA, and thus was found to be a partial agonist (Fig. 4, Table 2). In the 
presence of the allosteric modulators CGP7930 or GS39783 (30 µM each), the maximal 
stimulation obtained by CGP47656 was substantially increased by about 4-fold, to about the 
same maximal effect as the one obtained with a saturating concentration of GABA alone (Fig. 
4). The potency of CGP47656 in this assay was increased by 2- to 3-fold by the two 
modulators (Table 2). 
Some compounds previously described as competitive GABAB receptor antagonists 
(CGP35348, CGP52432, CGP54626, CGP56999, CGP62349, 2-OH-saclofen and SCH50911) 
were also tested in the GTP(γ)35S assay. As expected, when applied alone at different 
concentrations in the range of their antagonist potencies (or binding affinities), none of them 
stimulated GTP(γ)35S binding, confirming that these compounds are devoid of intrinsic 
agonistic activity in this assay (see Fig. 4 for two representative examples). However, in the 
presence of 30 µM GS39783 or CGP7930, two of the antagonists, CGP35348 and 
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Fig. 4. GTP(γ)35S binding to membranes from a recombinant CHO cell line stably expressing 
GABAB receptors. The stimulation of GTP(γ)35S binding by CGP47656 (top), CGP35348 (middle) 
and 2-OH-saclofen (bottom) was measured in the absence of modulators (squares) or in the presence 
of 30 µM CGP7930 (triangles) or 30 µM GS39783 (circles). The data represent the stimulation above 
basal activity relative to the effect of a maximally active concentration of GABA (100 µM) alone. The 
data points are means ± SEM from quadruplicate determinations. 
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Control + 30µM CGP7930 +30µM GS39783 
compound pEC50 
(-log M) 
EC50 
(µM) 
Max. 
Effect  
(%) 
pEC50 
(-log M) 
EC50 
(µM) 
Max. 
Effect  
(%) 
pEC50 
(-log M) 
EC50 
(µM) 
Max. 
Effect  
(%) 
CGP47656 5.98 ± 0.08 (4) 1.11 25 ± 2.7 
6.43 ± 0.07 
(5) ** 0.39 
105 ± 12  
** 
6.33 ± 0.07 
(5) * 0.50 
109 ± 10  
** 
CGP35348 -- --  0 5.7 ± 0.04 (7) 2.1 36 ± 3  ** 
5.5 ± 0.07 
(7) 3.0 
37 ± 5 
** 
2-OH-
saclofen -- --  0 
5.11 ± 0.18 
(4) 7.76 
31 ± 2.9 
** 
4.96 ± 0.10 
(4) 11 
35 ± 4 
** 
 
Table 2. Effects of allosteric modulators on potencies and efficacies of a partial agonist and 
neutral antagonists to enhance GTP(γ)35S binding stimulated by recombinant GABAB receptors 
expressed in CHO cells. Concentration-response curves for CGP47656, CGP35348 and 2-OH-
saclofen (Fig. 4) were measured in membranes from CHO cells stably expressing GABAB receptors, in 
the absence and in the presence of a fixed concentration (30µM) of allosteric modulators. The 
maximal stimulation above basal activity (i.e., the relative intrinsic efficacy of partial agonists) is 
expressed in percent of the effects obtained with a saturating concentration of GABA (100µM) alone. 
The Hill-coefficients of the concentration-response curves were not significantly different from one. 
The data shown are means ± SEM from (N) independent experiments.  *: p<0.05, **: p<0.01 
compared to the corresponding control values (ANOVA / Dunnett’s test). Because CGP35348 and 2-
OH-saclofen were inactive under control conditions, this statistical analysis could not be performed for 
the pEC50 values of these two compounds. Their maximal effects, however, were significantly 
different from zero (** p < 0.01, one sample t-test). 
 
2-OH-saclofen, stimulated GTP(γ)35S binding to maximally 30–40% of the full GABA effect, 
i.e., they became partial agonists at the GABAB receptor (Fig. 5 and Table 2). The other 
antagonists tested remained “neutral” or “silent” in the GTP(γ)35S binding experiments, also 
in the presence of the two allosteric modulators (data not shown). 
 
Regulation of cAMP formation in a recombinant cell line stably expressing GABAB 
receptors. The stimulation of adenylyl cyclase activity by the forskolin analog 7β-forskolin 
(Laurenza et al. 1987) in a recombinant GABAB receptor expressing CHO cell line was 
inhibited by GABA in a concentration-dependent manner (Fig. 5a). The inhibition of cAMP 
formation by GABA was reverted by the competitive antagonist CGP56999, and no effect of 
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GABA was seen in CHO cells which had not been transfected with cDNA encoding the 
GABAB receptor (data not shown). The potency of GABA was enhanced by CGP7930 and 
GS39783; although GABA produced a close to full inhibition of adenylyl cyclase activity by 
itself, a small further increase in the maximal inhibition by the modulators was seen as a trend 
(Fig. 5a, Table 3). As can be seen from the respective control levels in Fig. 5,  CGP7930 and 
GS39783 produced a small inhibition of cAMP formation by themselves. Although this effect 
was observed quite consistently in our experiments, its small magnitude precluded 
determining EC50 values for the two modulators. With the partial agonist CGP47656, an 
increase of both the potency and the maximal effect of adenylyl cyclase inhibition was 
observed in the presence of the modulators. In this assay system, CGP35348 and 2-OH-
saclofen, applied alone, turned out to be low efficacy partial agonists. Again, both 
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Fig. 5. 7β-forskolin stimulated adenylyl cyclase activity in a recombinant CHO cell line stably 
expressing GABAB receptors. The inhibition of cAMP formation by GABA (a), CGP47656 (b), 2-
OH-saclofen (c) and CGP35348 (d) was measured in the absence (filled squares) or in the presence of 
10µM CGP7930 (filled triangles) or 10 µM GS39783 (filled circles). The control values in the absence 
or presence of the modulators are indicated by the corresponding open symbols. The dotted lines 
represent basal cAMP levels. The data shown represent means ± SEM from triplicate (controls: 
quadruplicate) determinations. The results from several such experiments are summarized in Table 3.  
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Control + 10 µM CGP7930 +10 µM GS39783  
 
Compound 
pEC50 
(-log M) 
EC50 
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GABA 7.08 ± 0.05 (7) 83 nM 83 ± 1 
7.45 ± 0.09 
(7) ** 35 nM 86 ± 1.8 
7.64 ± 0.09 
(6) ** 23 nM 85 ± 1.4 
CGP47656 6.62 ± 0.09 (4) 240 nM 70 ± 4.9 
6.95 ± 0.07 
(4) * 112 nM 
78 ± 2.8 
* 
7.04 ± 0.11 
(4) * 91 nM 
79 ± 3.2 
* 
CGP35348 5.41 ± 0.05 (5) 3.9 µM 55 ± 4.7 
5.72 ± 0.16 
(4)  1.9 µM 
71 ± 1.9 
* 
5.83 ± 0.08 
(4) * 1.5 µM 67 ± 5.3 
2-OH-saclofen 4.65 ± 0.08 (6) 22.4 µM 46 ± 8.9 4.97 ± 0.35 10.8 µM 55 ± 6 
5.13 ± 0.29 
(6)  * 7.5 µM 
65 ± 8.4 
** 
 
 
Table 3. Effects of allosteric modulators on the potencies and efficacies of partial and full agonists to 
inhibit adenylyl cyclase activity in a recombinant GABAB receptor expressing cell line. Concentration-
response curves for GABA, CGP47656, CGP35348 and 2-OH-saclofen (Fig. 5) were measured in 
CHO cells stably expressing GABAB receptors, in the absence and in the presence of a fixed 
concentration (10µM) of allosteric modulators. The maximal effects are expressed in percent 
inhibition of the control stimulation obtained with 100 µM 7β-forskolin above basal cAMP levels. The 
Hill-coefficients of the concentration-response curves were not significantly different from one. The 
data shown are means ± SEM from (N) independent experiments.  *: p<0.05, **: p<0.01 compared to 
the corresponding control values (ANOVA / Dunnett’s test).  
 
 
 
their potencies and maximal efficacies were enhanced by CGP7930 and GS39783 (Fig. 5, 
Table 3). With CGP52432, results suggestive of inverse agonism were seen as a trend (data 
not shown); it marginally increased the formation of cAMP induced by 7β-forskolin by 
maximally 25 ± 5%. The inverse agonistic potency of CGP52432 seemed to be decreased by 
the allosteric modulators (pEC50 = 6.6 ± 0.2 and 6.8 ± 0.2 in the presence of 10µM CGP7930 
or GS39783, respectively, compared to 7.5 ± 0.1 (N=7) in the absence of modulators). The 
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other compounds tested (CGP54626, CGP56999, CGP62349 and SCH50911) did not affect 
7β-forskolin stimulated cAMP formation (data not shown). 
 
5.1.5. Discussion 
According to the TCM (Fig. 4 in Chapter 4) an orthosteric and an allosteric ligand mutually 
influence each other’s binding affinities to the same extent, which is determined by the 
allosteric constant γ. The formalism of the TCM does not at all take into account the intrinsic 
efficacies of the compounds, i.e. whether the orthosteric ligand is an agonist or an antagonist. 
Therefore, the binding affinities of competitive antagonists are expected to be amenable to 
allosteric modulation like those of agonists. This prediction has been entirely confirmed in the 
present study. In saturation experiments, it has been shown that the affinity of the antagonist 
radioligand [3H]-CGP62349 for native GABAB receptors is decreased by the allosteric 
modulators CGP7930 and GS39783, whereas the maximal binding capacity remains 
unchanged (Fig. 2). The affinities of several other compounds previously known to be 
GABAB receptor antagonists CGP52432, CGP54626, CGP56999, CGP62349 (Froestl and 
Mickel 1997; Bowery et al. 2002) and SCH50911 (Bolser et al. 1995) were also decreased in 
displacement experiments (Table 1). Only with 2-OH-saclofen (Kerr et al. 1988) and 
CGP35348 (Olpe et al. 1990) a small, but not significant, trend toward an increase in binding 
affinity was observed in the presence of the two modulators (Table 1). However, these two 
compounds were found in our functional assays not to be completely devoid of intrinsic 
agonist activity (see below). Previously, we have observed that CGP7930 and GS39783 
produced increases in the affinities of both high affinity (G protein – coupled) and low affinity 
states of native GABAB receptors for agonists (Urwyler et al. 2003; Urwyler, Gjoni et al. 
2004). At the same time, the relative proportion of high agonist affinity states was increased 
by the modulators. In the experiments shown here, we also found biphasic binding curves 
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with CGP47656, but only the high affinity component was affected by the modulators (Table 
1). It seems possible that the somewhat lesser effects of the two modulators on the binding of 
CGP47656 to GABAB receptors are related to the partial agonistic nature of this compound. 
 
Similar to the allosteric constant γ in the TCM (affecting binding affinities), the extended two-
state model of receptor activation (Hall 2000) introduces a factor δ by which the intrinsic 
efficacy of an orthosteric ligand (α) may change under the influence of an allosteric agent. 
This concept explains the finding, quite unique at the time of the discovery of CGP7930, that 
allosteric modulators are able to increase the maximal GABAB receptor stimulation produced 
by agonists. Here we show that the same phenomenon occurs with the partial agonist 
CGP47656 (Froestl et al. 1995; Knight and Bowery 1996). The efficacy of this compound 
was modulated by CGP7930 and GS39783 even more strongly than that of GABA. In fact, in 
the GTP(γ)35S assay its maximal effect was increased by about a four-fold by both modulators 
(Fig. 4, Table 2), whereas 1.5 to 2-fold increases were reported previously for their effects on 
GABA (Urwyler et al. 2001 and 2003). Apparently, the less  efficacious receptor activation 
with a partial agonist leaves more room for positive modulation. Different degrees of 
increases in efficacies produced by an allosteric modulator with different partial or full 
agonists have also recently been reported for the mGluR2 receptor (Schaffhauser et al. 2003). 
 
We have found two compounds, CGP35348 and 2-OH-saclofen, which did not stimulate 
GTP(γ)35S binding at all on their own, but became partial GABAB receptor agonists in the 
presence of the allosteric modulators (Fig. 4). These compounds are both structurally closely 
related to two well known GABAB receptor agonists, APPA and baclofen (Fig. 1). Like that 
of other “family 3” GPCRs, the orthosteric binding site of GABAB receptors consists of a 
“Venus flytrap module” (VFTM), two hinge lobes in the large extracellular domain, which 
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oscillate between open and closed states. The binding of an agonist in the cleft between the 
lobes causes them to close, whereby the agonist is trapped (Galvez et al. 1999 and 2000a; Pin 
et al. 2003). It seems that although CGP35348 and 2-OH-saclofen are still able to bind to the 
receptor pocket, the chemical modifications which distinguish them from APPA and baclofen 
prevent them from activating the receptor by closing the VFTM (smaller modifications in 
CGP47656, compared to CGP35348 [Fig. 1], result only in a partial loss of efficacy). 
However, the conformational change induced in the receptor by the allosteric modulators 
obviously results in a better fit of these molecules, not only increasing their affinities, but to a 
certain extent also their intrinsic efficacies. Another example of changes in the receptor-ligand 
interaction at the orthosteric binding site of a family 3 GPCR, which convert antagonists into 
agonists has been reported by Bessis et al. (2002). In that case, structural changes in the 
VFTM (site directed mutations of two critical amino acids) converted two mGluR8 
antagonists into agonists. In our case, it does not become clear from the GTP(γ)35S 
experiments whether the modulators confer partial agonistic activity to otherwise completely 
silent antagonists (α = 1,  δ > 1), or whether CGP35348 and 2-OH-saclofen possess some 
marginal agonistic properties, which cannot be detected in this assay under normal 
circumstances but are unmasked by the allosteric modulators. According to recent concepts, 
neutral antagonists that bind to receptors without altering the equilibrium between their active 
and inactive states at all, i.e. having an intrinsic efficacy constant α of exactly one (Figs 3, 4 
and 5 in Chapter 4) are likely to be rare (Kenakin 2004). Compounds appearing at first as 
“silent” antagonists may in reality be low efficacy partial agonists or inverse agonists (Strange 
2002; Kenakin 2004). The detection of inverse agonism depends on the availability of an 
assay system with measurable constitutive receptor activity f. On the other hand, the detection 
of low efficacy partial agonism is facilitated in a system with a high degree of receptor 
reserve.  
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GABAB receptor agonists inhibit forskolin-stimulated activity of adenylyl cyclase in native 
and recombinant assay systems (Wojcik and Neff 1984; Karbon and Enna 1985; Hirst et al. 
2003). Recently, it has been shown that CGP7930 enhances this effect in rat brain 
preparations (Onali et al. 2003), and here we show the same to occur with both modulators in 
a recombinant cell line expressing GABAB receptors (Fig. 5, Table 3). In this assay system, 
the partial agonist CGP47656 had an intrinsic efficacy which was higher than that found in 
GTP(γ)35S experiments (Fig. 4). This discrepancy is likely due to the existence of a large 
receptor reserve in the cAMP assay system, as suggested by the much higher potency of  
GABA (EC50 = 83 nM) when compared to the GTP(γ)35S assay (EC50 = 4.9 µM, Urwyler et 
al. 2001). This interpretation is further corroborated by the finding that the partial agonistic 
nature of CGP35348 and 2-OH-saclofen, which was hidden in the GTP(γ)S assay and only 
revealed by the allosteric modulators, was visible in the cAMP assay even when the 
compounds were applied on their own. Both the potencies and the maximal inhibitions 
produced by CGP47656, CGP35348 and 2-OH-saclofen were enhanced by GS39783 and 
CGP7930. Interestingly, the allosteric modulators CGP7930 and GS39783 also had some 
small inhibitory effect on cAMP formation on their own, whereas they had been found 
previously to be devoid of any intrinsic activity at GABAB receptors in various assay systems 
(Urwyler et al. 2001 and 2003). This is again in line with the existence of a large receptor 
reserve in the cAMP signaling pathway. Recently, Binet et al. (2004) have also reported that 
CGP7930 is a partial agonist in a seemingly even more sensitive assay system with a high 
degree of receptor reserve, by directly activating the heptahelical domain of GABAB(2). This is 
not at variance with the concept of allosteric modulation, since the extended ternary complex 
model allows for allosteric modulators having some efficacy on their own via the allosteric 
binding site (β, see Fig. 5 in Chapter 4). SCH50911 and CGP54626 have recently been 
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reported to be inverse agonists in cAMP assays with recombinant GABAB receptors 
(Grünewald et al. 2003; Hirst et al. 2003). We found inverse agonism as a trend only with 
CGP52432. It is not clear whether low intrinsic inverse agonist efficacies or a small 
constitutive activity of the GABAB receptor in our recombinant cell line explain why we have 
not detected any inverse agonism with SCH50911 and CGP54626, and possibly also with 
CGP56999 and CGP62349. 
 
In conclusion, this study shows that agonists and competitive antagonists at GABAB receptors 
are amenable to allosteric modulation by CGP7930 and GS39783. Whereas the positive 
modulators enhance agonist affinity by further stabilizing the closed conformation of the 
VFTM, they decrease the affinities of silent competitive antagonists or inverse agonists, 
which bind to or even stabilize the open state of the VFTM. They also enhance the intrinsic 
efficacies of partial and full agonists, thus making possible the detection of partial agonism in 
little sensitive systems such as the GTP(γ)35S assay. The cAMP signaling cascade in a 
recombinant cell line, due to its high degree of receptor reserve, also is a very sensitive assay 
system to detect partial agonism at the GABAB receptor. Compounds believed to be “silent” 
competitive antagonists are often used as tools for pharmacological studies in vitro and in 
vivo. In a physiological context, especially in vivo and unlike in a recombinant cell line, 
important variables such as constitutive receptor activity and receptor reserve are largely 
unknown, and hidden partial or inverse agonistic effects of such compounds might introduce 
unpredictable confounding effects. Therefore, powerful tools, such as suitable cellular assay 
systems in conjunction with allosteric modulators, to unmask the true intrinsic properties of 
orthosteric ligands, should be of great value. 
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5.2. Receptor activation involving positive allosteric modulation, unlike full 
agonism, does not result in GABAB receptor desensitization: an in vitro 
study 
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5.2.1. Abstract 
Allosteric modulators act more physiologically than orthosteric ligands, targeting only 
endogenously activated receptors and not their whole population, which is why they are 
expected to produce less side-effects and tolerance. To inspect the role of the positive 
allosteric modulator GS39783 in GABAB receptor desensitization, we examined receptor 
function and cell surface expression in a recombinant GABAB cell line and in primary 
neuronal cultures upon persistent treatments with GABAB agonists, and combinations of 
agonists and GS39783. The potency of GABA to inhibit 7β-forskolin-induced cAMP 
formation in recombinant cells decreased after the exposure to a saturating GABA 
concentration, but not after a combination of a low GABA concentration and GS39783, that 
activated the receptor to the same extent. Concordantly, a significant decrease of cell surface 
receptors was found after GABA-induced desensitization, unlike after the combined treatment 
with GABA and GS39738. Similar observations regarding receptor function were found in 
primary neurons for baclofen-induced inhibition of spontaneous Ca2+ oscillations. However, 
the cell surface receptor density remained unaffected upon baclofen-induced desensitization 
in the primary neurons, possibly due to different mechanisms of desensitization in the neurons 
and the recombinant cell line. These findings indicate that the degree of occupancy of the 
orthosteric site determines desensitization rather than  the degree of receptor activation. In 
summary, our results conform to predictions that positive allosteric modulators have less 
propensity for the development of tolerance due to receptor desensitization than classical 
agonists. 
 
Abbreviations: GABA, γ-aminobutyric acid; GPCR, G-protein-coupled receptor; mGluR 
metabotropic glutamate receptor; CHO, Chinese hamster ovary; CNS, central nervous system; 
CPA, N6-cyclopentyladenosine; GTP(γ)S, guanosine 5'-O-(3-thiotriphosphate); DIV, day in 
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vitro; FLIPR, fluorescence imaging plate reader; HBSS, Hanks’ buffered salt solution; HEK, 
human embryonic kidney.   
 
 5.2.2. Introduction 
G-protein coupled receptors (GPCRs) represent the most “popular” drug targets in modern 
pharmacology: more than 1000 membrane-bound receptors compose the GPCR superfamily 
and almost 40% of all the pharmaceuticals on the market today act through them, mainly by 
binding as agonists or antagonists to the same (“orthosteric”) site as their endogenous ligands  
(Hopkins and Groom 2002; Maudsley et al. 2005). The use of such drugs is, however, often 
limited by their side-effects and/or receptor up- and downregulation underlying tolerance 
(Gainetdinov et al. 2004). 
Allosteric modulation, an alternative way of acting at GPCRs, is expected to be devoid of 
abovementioned disadvantages. Allosteric modulators are substances that bind to and act 
through topographically distinct (“allosteric”) sites on receptors than orthosteric ligands. 
Positive modulators act synergistically with agonist-induced receptor activation by enhancing 
it. Many of them do not stimulate receptors on their own. Their action is, therefore, in concert 
with physiological signaling, both temporally and spatially. Because of this use-dependent 
mechanism, they are expected to produce less side-effects and tolerance than orthosteric drugs 
(Christopoulos 2002; Christopoulos and Kenakin 2002; Langmead and Christopoulos 2006). 
Despite the fact that allosteric modulators of GPCRs are presently in the focus of 
pharmacological research, so far there have been only few studies performed to assess 
whether they play a role in GPCR desensitization and downregulation (Klaasse et al. 2005; 
May et al. 2005; Bhattacharya and Linden 1996). 
GABA is the major inhibitory neurotransmitter in the CNS, the action of which is mediated 
via ionotropic GABAA and GABAC receptors and the metabotropic GABAB receptor. 
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Dysfunctions of the GABAergic neurotransmission in the CNS have been linked with many 
disorders such as epilepsy, spasticity, anxiety, stress, sleep disorders, depression, addiction 
and pain. Heterodimeric GABAB receptors belong to the family 3 of GPCRs together with the 
metabotropic glutamate receptors, the calcium-sensing receptors and mammalian taste and 
odorant receptors (Pin et al. 2003). They mediate slow synaptic inhibition by negative 
coupling to adenylyl cyclase and modulating voltage-gated calcium channels and inwardly 
rectifying potassium channels (reviewed in Bowery et al. 2002). 
The only marketed drug that acts via the GABAB receptor is its selective agonist baclofen, 
introduced in the clinical practice as an anti-spastic agent more than thirty years ago. 
However, side-effects as well as rapid development of tolerance are its main shortcomings 
(Malcangio et al. 1992; Lehmann et al. 2003; Malcangio et al. 1995, reviewed in Vacher and 
Bettler 2003). 
This explains the interest in the recently discovered positive allosteric modulators of GABAB 
receptors CGP7930 and GS39783 (Urwyler et al. 2001 and 2003). They were found to 
increase both the affinity and the efficacy of agonists, with none or very little effect in their 
absence, in many assay systems in vitro (Urwyler et al. 2001 and 2003; Urwyler, Gjoni et al. 
2005; Onali et al. 2003; Olianas et al. 2005) and in vivo (Gjoni et al. 2006). 
In this study, we aimed to investigate whether receptor activation involving positive allosteric 
modulation leads to GABAB receptor desensitization. To this end, we have used both a 
recombinant (a cell line stably expressing the GABAB receptor) and a native assay system 
(mouse primary neuronal cortical cultures). Our key strategy was to persistently activate the 
receptor either with desensitizing agonist concentrations or with combinations of low agonist 
concentrations and GS39783 that activate the receptor to the same extent. The functional 
responses of the receptor as well as the cell-surface receptor expression were then compared 
after these different pretreatments. 
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5.2.3. Materials and Methods 
Materials: GS39783, R(-)-baclofen, S(+)-baclofen, CGP56999, CGP52432 and CGP54626 
were available in-house. Mastoparan was purchased from Tocris bioscience, UK. Stock 
solutions of R(-)-baclofen, S(+)-baclofen, CGP56999, CGP52432 and CGP54626 were made 
in appropriate experiment buffers freshly before each experiment. GS39783 was dissolved in 
DMSO to give a stock solution that was further diluted in appropriate buffers. Sources of 
other chemicals are given in method descriptions. 
 
Adenylyl cyclase assays in a recombinant cell line stably expressing GABAB receptors: A 
stable Chinese hamster ovary (CHO) cell line co-expressing human GABAB(1b) together with 
rat GABAB(2) (Urwyler et al. 2001) was cultured in Dulbecco's modified eagle medium 
(DMEM, glutamine-free, Invitrogen, Basel, Switzerland) supplemented with 10% fetal calf 
serum, 20 µg/ml L-proline, 500 µM glutamine, 1 mg/ml geneticin, 250 µg/ml zeocin). The 
cells were grown to 80–90% confluency in 15 cm cell culture dishes. Prior to the cAMP 
measurement, they were treated with the appropriate concentrations of agonists and GS39783 
diluted in the cell growth medium for 2 hours. After the pretreatment, cells were washed twice 
with PBS. The cAMP accumulation experiment was then performed as has been described 
previously (see Urwyler, Gjoni et al. 2005 for details). 
 
Calcium oscillations in neuronal networks: Primary cultures of cortical neurons were 
prepared from embryonic (day 16 to 18) BALB/c mice (adapted from Wang and Gruenstein 
1997, as described in Urwyler et al. 2001). Dissociated cells were plated on poly-D-lysine 
coated 96-well plates at ca. 60’000 cells/well in 200 µL medium and incubated at 37°C in 5% 
CO2 for 7 to 10 days. Half of the medium was changed every 2 days. Two hours before the 
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experiment, half of the medium was replaced with fresh medium or fresh medium containing 
R(-)-baclofen, S(+)-baclofen, GS39783 and CGP52432 or their combinations to give the final 
concentrations described in the Subsection 5.2.4. 
After the preincubation period, the culture medium was removed, cells were washed twice 
with Hank’s buffered saline solution (HBSS, Invitrogen, Switzerland) supplemented with 10 
mM HEPES (pH adjusted to 7.4) and loaded with 2 µM fluo-4 AM in the same buffer. After 
loading (10 min), cells were washed twice with Mg2+-free HBSS/10 mM HEPES and then 
transferred to the fluorescence imaging plate reader (FLIPR). Fluorescence was measured at 
room temperature and at a sampling rate of 0.5 Hz for 10 minutes. Drugs were dissolved in 
Mg2+-free HBSS and added to the cultures during recording. Oscillations were analyzed using 
IgorPro (Wavemetrics, Lake Oswego, OR) by peak detection and calculation of the ratio of 
peak frequencies before and after compound addition. 
 
Cell surface [3H]-CGP62349 labeling in the recombinant GABAB cell line. The CHO-K1 
cells stably expressing the GABAB receptor (vide supra) were grown to confluency, treated, 
washed and  trypsinized as described above. The cells were counted, resuspended in Krebs-
Tris 7.4 buffer (20 mM Tris HCl pH 7.4, 118 mM NaCl, 4.7 mM KCl, 1.8 mM CaCl2, 1.2 
mM KH2PO4, 1.2 mM MgSO4, 5.6 mM D(+)-glucose) and 200’000 cells were dispensed per 
well. A high-affinity GABAB selective radioligand [3H]-CGP62349 (85 Ci/mMol, American 
Radiolabeled Chemicals Inc., St. Louis, MO) was added at a saturating concentration (15 nM) 
and incubated with the cells while mildly shaking for 20 min. Nonspecific binding was 
measured in the presence of the GABAB specific antagonist CGP54626 (1 µM). After the 
incubation, the cell suspension was filtered on a Packard Filtermate Harvester and 50 µL/well 
of scintillation fluid was added. The plate was shaken for 1 hour and counted on a Packard 
TopCount NXT (counting time: 20 min/well). 
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Protein concentrations for the samples in each treatment group were measured with the 
Bradford assay method, using the Bio-Rad protein assay kit and bovine serum albumin as a 
standard, and the specific binding was expressed relative to protein content. 
To verify that the radioligand [3H]-CGP62349 does not cross the cell membrane, Human 
embryonic kidney (HEK-FT) cells were transfected either with human GABAB(1a) subunit 
alone (8 µg) or with human GABAB(1a) (8 µg) and rat GABAB(2) (16 µg) subunits together 
(Fugene 6, Roche, Switzerland). 48h post-transfection, the binding experiment with whole 
cells was performed as described above. Also, the same procedure was applied to membranes 
prepared (as described previously in Urwyler et al. 2001) from cells transfected with human 
GABAB(1a) or human GABAB(1a) and rat GABAB(2). 
 
Cell surface [3H]-CGP62349 labeling in mouse cortical neuronal cultures: Cortical neuronal 
cultures were prepared from BALB/c mice, seeded and maintained as described above. Two 
hours before the experiment, half of the medium was replaced either with fresh medium or 
fresh medium containing R(-)-baclofen. The cells were then washed twice with HBSS 
supplemented with 10 mM HEPES (pH adjusted to 7.4), a saturating concentration of [3H]-
CGP62349 (15 nM) in Krebs-Tris buffer, or the mix of the radioligand with 1 µM CGP54626 
for the assessment of nonspecific binding, was added to each well and the plate was shaking 
for 20 minutes. The plate was put on ice and cells were washed three times with cold Krebs-
Tris buffer to remove the unbound radioligand. 200 µL of 0.1 M NaOH was added to each 
well and the plate was left to shake for 20 minutes. The contents of three wells were pooled 
into one vial and an aliquot was removed for protein content analysis. Scintillation fluid was 
added to each vial, vials were shaken for 1h and measured on a Packard TRI-CARB 3100TR 
Liquid Scintillation Analyzer (counting time 20 min per vial). 
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5.2.4. Results 
cAMP measurement in CHO-K1 cells stably expressing the GABAB receptor. To 
examine the effect of prolonged pretreatments of GABAB receptor-expressing cells with 
GABA, GS39783 and their combinations, inhibition of cAMP formation stimulated by 7β-
forskolin was measured as a readout of GABAB receptor activation. The concentrations for 
the pretreatments were chosen on the basis of the previously obtained GTP(γ)S assay data 
(Urwyler et al. 2003). In the GTP(γ)S experimental system, receptor activation corresponds to 
occupancy (same agonist potencies as binding affinities) and thus seems to be devoid of 
receptor reserve, which would have had confounding effects in our experimental design. As 
has been shown previously (Gonzales-Maeso et al. 2003), after a two-hour exposure to a 
saturating GABA concentration (100 µM),  the potency of GABA to inhibit cAMP production 
significantly decreased as well as its maximal effect (Fig. 1).  
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Fig. 1. cAMP measurement in a recombinant cell line stably expressing GABAB receptors. 
Comparison of the effects of different cell pretreatments (2h) on agonist potency and efficacy. Control: 
squares, 100 µM GABA: circles, 0.3 µM GABA + 10 µM GS39783: triangles, 100 µM GABA + 10 
µM GS39783: diamonds. These are representative curves done in triplicates (means ± SEM). The data 
from several such experiments are summarized in Table 1. 
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GABA 
Pretreatment conditions (2h): 
pEC50 EC50 
Maximal 
inhibition (%) N 
Control (no pretreatment) 6.95 ± 0.03 118 nM 84.4 ± 1.2 25 
GABA, 100 µM  6.25 ± 0.06** 653 nM 71.6 ± 3.4* 16 
GABA, 0.3 µM + GS39783, 10 µM  7.08 ± 0.06 90 nM 90.4 ± 2.1 9 
GABA, 100 µM + GS39783, 10 µM 6.21 ± 0.04**  622 nM  70.6 ± 8.3** _ 4 
 
Table 1. Effects of different pretreatments (2h) on the potency and maximal effect of GABA to inhibit 
7β-forskolin-induced cAMP production. Concentration-response curves with GABA were measured in 
CHO cells stably expressing GABAB receptors after different pretreatments. The maximal effects are 
expressed in percent inhibition of the control stimulation obtained with 100 µM 7β-forskolin above 
basal cAMP values. The data shown are means ± SEM from (N) independent experiments. * p<0.05, 
** p<0.01 vs. control group (no pretreatment), one-way ANOVA, Dunnett’s test. 
 
 
 
Similar effects were observed with R(-)-baclofen, but not with its inactive S(+)-enantiomer 
(data not shown). However, the exposure to a combination of a low GABA concentration (0.3 
µM) and GS39783 (10 µM), that activated the receptor to the same extent as 100 µM GABA 
alone, did not lead to desensitization. On the other hand, when the cells were incubated with a 
saturating GABA concentration and the positive allosteric modulator GS39783 (100 and 10 
µM, respectively), desensitization of the GABAB receptors still occurred (Table 1, Fig. 1). 
The pretreatment with GS39783 alone, did not lead to receptor desensitization (data not 
shown). 
The responsiveness of adenylyl cyclase to mastoparan, a direct activator of Gi/o signaling, to 
inhibit cAMP, was the same in the control and the pretreated cells (data not shown). 
To verify that there were no confounding effects of GS39783 accidentally carried over from 
the pretreatment containing GS39783, LC/MS analysis of washing and assay buffers was 
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performed and showed that there was no GS39783 left in the assay buffer (data not shown, 
courtesy of Dr. M. Koller, internal communication). 
 
GABAB receptor cell surface labeling with [3H]-CGP62349 in the recombinant cell line. 
Radioligand binding with a saturating concentration of the selective GABAB receptor 
antagonist [3H]-CGP62349 was employed to investigate cell-surface receptor expression upon 
different two-hour pretreatments (vide supra). Bmax values were calculated for each 
pretreatment. Firstly, to verify that the radioligand does not cross the cell-membrane, we took 
advantage of the fact that the GABAB(1) subunit containing the ligand binding site, is not 
expressed at the cell surface in the absence of the GABAB(2) subunit (Pagano et al. 2001). 
Binding experiments were performed on intact cells transiently expressing the human 
GABAB(1a) subunit alone, or the human GABAB(1a) and rat GABAB(2) subunit together. 
Additionally, binding was measured on membranes prepared from cells transiently expressing 
the human GABAB(1a) subunit alone. There was substantial specific binding either when both 
receptor subunits were expressed in intact cells or when membranes were prepared from cells 
expressing the human GABAB(1a) subunit alone, but there was no specific binding on intact 
cells expressing only the human GABAB(1a) subunit (data not shown). 
In line with the functional readout, a two-hour preincubation with the saturating concentration 
(100 µM) of GABA led to a significant decrease of cell surface receptor labeling by 23 ± 
2%**. In contrast, exposing the receptor to a combination of low GABA and the allosteric 
modulator GS39783 (0.3 and 10 µM, respectively) that activate the receptor to the same 
extent as a desensitizing GABA concentration (100 µM), the cell-surface binding of the 
radioligand remained same as in the control group. On the other hand, when the cells were 
incubated with a saturating GABA concentration and the positive allosteric modulator 
GS39783 (100 and 10 µM, respectively), there was a reduction of 24 ± 2 %** in the cell 
surface binding (means ± SEM, N=8, **p<0.01, One-way ANOVA, Dunnett’s test) (Fig. 2). 
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Figure 2. Assessment of GABAB receptor cell-surface expression upon different two-hour 
pretreatments. Their effects on receptor number were measured by radiolabeling with a saturating  
concentration of [3H]-CGP62349 (15 nM). Control: white bar, 100 µM GABA: vertical stripes, 100 
µM GABA + 10 µM GS39783: checkered bar, 0.3 µM GABA + 10 µM GS39783: horizontal stripes. 
Data are means ± SEM of a typical experiment done in sextuplicates. ** p<0.01, One-way ANOVA 
vs. control followed by Dunnett’s test. 
 
R(-)-baclofen-mediated inhibition of spontaneous Ca2+ oscillations in primary mouse 
neuronal cultures is enhanced by GS39783. In order to observe these phenomena in a 
native system, experiments were carried out in mouse primary cortical neurons. As has been 
shown previously, when dissociated neurons are plated densely and left for sufficient time 
(DIV 6-10) in culture, they form a network. In the absence of Mg2+ in the medium, 
spontaneous oscillations of intracellular Ca2+ concentrations are observed in this network 
reflecting the net outcome in excitatory and inhibitory signaling (Wang and Gruenstein 1997). 
We have shown previously that these spontaneous oscillations of  Ca2+ are inhibited when the 
GABAB receptor is activated (Urwyler et al. 2001). In the first series of experiments 
establishing a concentration-response relationship for R(-)-baclofen to inhibit spontaneous 
Ca2+ spikes, the pEC50 of the agonist was found to be 6.01 ± 0.04 (means ± SEM, N=12) (Fig. 
3a). This inhibition was antagonized by the potent and GABAB selective antagonist 
CGP56999 and the relative Ca2+ spiking frequency was brought back to the control level (Fig. 
3a). In the presence of the GABAB positive allosteric modulator GS39783 at 1 and  
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Fig. 3. (a) Inhibition of spontaneous Ca2+ oscillations (no drug added: open squares connected by a 
dotted line) in mouse primary cortical neurons by R(-)-baclofen (filled squares, full lines) enhanced in 
the presence of 1 (open circles) and 3 µM (filled squares) GS39783. GABAB competitive antagonist 
CGP56999 (1 µM) brings the R(-)-baclofen-inhibited (10 µM) spiking frequency back to the control 
level (open diamonds connected by a dotted line). The graph shows typical curves done in 
quadruplicates as means ± SEM Corresponding pEC50 values are indicated in the text. (b) Two-hour 
pretreatments with 10 (N=3) and 100 µM R(-)-baclofen (N=11), but not 3 µM (N=3), induce GABAB 
receptor desensitization. Data on the graph are differences in pEC50 between control and treated cells 
presented as means ± SEM One way ANOVA followed by Dunnett’s test, **p<0.01. (c) 
Desensitization of the GABAB response with prolonged activation (2h) with a saturating concentration 
(100 µM)  R(-)-baclofen can be inhibited with a selective GABAB antagonist CGP52432. 
Concentration-response curve of R(-)-baclofen inhibiting spontaneous Ca2+ spiking in unpretreated 
(control) cultures (filled squares, full line), 100 µM R(-)-baclofen-pretreated cultures (for 2h; 
desensitized cultures: filled circles, full line) and 100 µM R(-)-baclofen + 100 µM CGP52432-
pretreated cultures (antagonized desensitization: open squares, dotted line). Data are means ± SEM of 
representative curves done in quadruplicates. (d) Stereospecificity of the GABAB receptor 
desensitization. Concentration-response curve of R(-)-baclofen in non pretreated (control) cultures 
(filled squares, full line), 100 µM R(-)-baclofen-pretreated cultures (for 2h; desensitized cultures: 
filled circles, full line) and 100 µM S(+)-baclofen-pretreated cultures (for 2h; open circles, dotted 
line). Data are means ± SEM of one typical experiment done in quadruplicates. 
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3 µM, the potency of R(-)-baclofen to inhibit Ca2+ spikes significantly increased to pEC50 
values of 6.29 ± 0.07** (means ± SEM, N=6) and 6.46 ± 0.07** (means ± SEM, N=6, ** 
p<0.01 one way ANOVA followed by Tukey’s test), respectively (Fig. 3a). 
 
Desensitization of the GABAB receptors in primary cortical cultures. The ability of R(-)-
baclofen to inhibit spontaneous Ca2+ oscillations in primary cortical neurons was significantly 
decreased after a two-hour exposure to 10 and 100 µM R(-)-baclofen, but not to 3 µM (Fig. 
3b), i.e. the response of the GABAB receptors desensitized. Differences in R(-)-baclofen 
pEC50 values between control cells and cells treated with 3, 10 and 100 µM R(-)-baclofen 
were  0.13 ± 0.04 (N=3), 0.56 ± 0.08** (N=4) and 0.73 ± 0.05** (N=11) (**p<0.01, one-way 
ANOVA vs. control followed by Dunnett’s test), respectively (Fig. 3b). Desensitization 
induced with a 2h 100 µM R(-)-baclofen preincubation was successfully antagonized by a co-
pretreatment with the selective high affinity GABAB antagonist CGP52432 (Fig. 3c, Table 2).  
 
 
 
R(-)-baclofen Pretreatment conditions (2h): pEC50 EC50 N 
Control (no pretreatment) 6.12 ± 0.02 821 nM 44 
R(-)-baclofen, 100 µM  5.47 ± 0.04** 3.85 µM 24 
R(-)-baclofen, 100 µM + CGP52432, 100 µM  6.28 ± 0.15  623 nM 5 
S(+)-baclofen, 100 µM  5.98 ± 0.02  1.05 µM 2 
R(-)-baclofen, 3 µM + GS39783, 1 µM  6.19 ± 0.08  790 nM 8 
R(-)-baclofen, 100 µM + GS39783, 1 µM  5.99 ± 0.09 1.03 µM 6 
 
 
Table 2. Effects of different pretreatments (2h) on the potency of R(-)-baclofen to inhibit spontaneous 
Ca2+ oscillations in mouse primary neuronal cultures. The potencies of R(-)-baclofen were obtained 
from concentration-response curves measured after the indicated pretreatments. The data shown are 
means ± SEM from (N) independent experiments. ** p<0.01, compared vs. control group, one-way 
ANOVA vs. control (no pretreatment) and Tukey’s test. 
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Moreover, when the cultures were preincubated with the inactive enantiomer S(+)-baclofen, 
the potency of R(-)-baclofen stayed the same as in the control cultures (Fig. 3d), which further 
supports the conclusion that desensitization of the R(-)-baclofen response was GABAB 
receptor specific. When the cultures were preincubated with a combination of R(-)-baclofen 
(3 µM) and GS39783 (1 µM), that activated the GABAB receptor to the same extent as a 
saturating R(-)-baclofen concentration (100 µM), which desensitized the receptor, there was 
no desensitization of the GABAB receptors (Fig. 4, Table 2). Further, in contrast to our 
finding in the GABAB stably expressing cell-line, the presence of 1 µM GS39783 diminished 
the GABAB receptor desensitization which 100 µM R(-)-baclofen normally produced (Fig. 4, 
Table 2). The preincubation of the cultures with 1 µM GS39783 alone (2h) had no effects on 
either the R(-)-baclofen potency or the Ca2+ spiking pattern (data not shown). 
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Fig. 4. The role of GS39783 in the R(-)-baclofen-induced GABAB receptor desensitization in mouse 
primary cortical neurons. Concentration-response curve of R(-)-baclofen in non pretreated (control: 
filled squares, full line) cultures, 100 µM R(-)-baclofen- (filled circles, full line), 3 µM R(-)-baclofen + 
1 µM GS39783- (open triangles, dotted line) and 100 µM R(-)-baclofen + 1 µM GS39783-pretreated 
(2h) cultures (open circles, dotted line). Data on the graph are means ± SEM of typical curves done in 
quadruplicates. 
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Cell-surface GABAB receptor labeling in primary cortical neurons with [3H]-CGP62349. 
Contrary to the recombinant GABAB cell-line, there was no decrease in the cell-surface 
receptor expression in cultured primary neurons upon desensitization with 100 µM R(-)-
baclofen. The GABAB receptors at the cell surface amounted to 0.79 ± 0.02 fmol/µg protein 
(N=24) in the control group (no pretreatment) and 0.77 ± 0.02 fmol/µg protein (N=24) in the 
100 µM R(-)-baclofen pretreated group. The data are pooled from 5 experiments performed in 
pentuplicates, means ± SEM. 
 
5.2.5. Discussion 
Receptor desensitization, the most common cause underlying tolerance or lack of sustained 
efficacy, has been shown for many GPCRs after a persistent high degree of receptor activation 
(reviewed in Gainetdinov et al. 2004). Because of its use-dependent mechanism, it is expected 
that positive allosteric modulation has less potential to induce receptor desensitization. We 
have therefore set out to investigate whether this holds true in the case of the GABAB receptor 
and its positive allosteric modulator, GS39783, as predicted earlier (Pin et al. 2001). Our 
major finding is that GABAB receptor activation involving positive allosteric modulation by 
GS39783 did not lead to receptor desensitization. 
The approach used was to compare different two-hour pretreatments corresponding to equal 
degrees of receptor activation. They consisted of either a desensitization-inducing 
concentration of a GABAB agonist alone or of a combination of an agonist and the positive 
allosteric modulator GS39783. Assuming that it might be agonist-occupancy of the orthosteric 
binding site that drives desensitization, the choice of pretreatment concentrations was made 
on the basis of the GTP(γ)S assay system (Urwyler et al. 2003). Since the GTP(γ)S 
experimental paradigm seems to be devoid of receptor reserve, levels of receptor activation 
essentially correspond to receptor occupancy (further discussed in Urwyler, Gjoni et al. 2005 
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or Section 5.1.). Had the choice been based on a system with a high receptor reserve (e.g. 
cAMP measurement), induction of desensitization could have failed, as in such systems the 
receptor is maximally active even with low agonist occupancy. GABAB receptor function and 
the cell-surface receptor number were examined in both a recombinant and a native assay 
systems following the described pretreatments.  
Our results confirm that in both, the recombinant (inhibition of cAMP formation in the 
GABAB stable cell line) and the native (inhibition of Ca2+ oscillations in primary mouse 
cortical neurons) systems,  there was no functional desensitization after the pretreatment with 
a low concentration of agonist together with GS39783 (Figs 1 and 4) as opposed to the 
desensitization occurring following pretreatments with saturating concentrations of agonists. 
Given that the degrees of receptor activation were the same in the different pretreatments 
used, we conclude that it is indeed the degree of occupancy of the orthosteric binding site that 
determines whether the receptor desensitizes or not. From the known affinities of GABA 
alone and in the presence of GS39783 (Urwyler et al. 2003) it can be calculated that the 
occupancy of the orthosteric binding site by 100 µM GABA alone, that desensitized the 
receptor in the recombinant cell line, amounts to about 97%, whereas it is only approximately 
8% in the case of 0.3 µM GABA alone, which is the low agonist concentration used for the 
pretreatment combination with GS39783 (Fig. 1, Table 1). However, because the positive 
allosteric modulator GS39783 increases the binding affinity of agonists toward the receptor 
(Urwyler et al. 2003), the occupancy of the orthosteric site by 0.3 µM GABA in the presence 
of 10 µM GS39783 rose to ca. 35% which is apparently still not sufficient to lead to receptor 
desensitization. 
As predicted by the allosteric two-state model (Hall 2000), the enhancing influence of a 
positive allosteric modulator can be a result of its effect on agonist affinity, efficacy or a 
combination of both. The positive allosteric modulator GS39783 enhances both the affinity 
and the efficacy of GABAB agonists (Urwyler et al. 2003). However, it has been calculated 
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that it is the effect on agonist efficacy, rather than affinity, which is predominantly 
responsible for its positive modulatory action (May et al. 2007). Exertion of positive allosteric 
effects by primarily affecting the efficacy of agonists, seems to perfectly match the profile an 
ideal positive allosteric modulator should have. Oppositely, a positive allosteric modulator 
that acts by enhancing primarily the affinity of agonists, instead of their efficacy, will increase 
the occupancy of the orthosteric site, potentially leading to receptor desensitization. 
Although these mechanisms may differ from one receptor to another, a comparison with other 
GPCRs is worthwhile. In fact, little has been investigated regarding allosteric modulation and 
its effect on GPCR desensitization and no study pursuing a strategy similar to ours has been, 
to our knowledge, published to date. Together with a report on the lasting effects of negative 
allosteric modulators on M2 muscarinic acetylcholine receptor (May et al. 2005), only studies 
examining long term receptor activation involving positive allosteric modulation were 
conducted on the adenosine A1 receptors and its allosteric enhancers PD81’723 and T62. 
Bhattacharya and Linden (1996) reported desensitization after a pretreatment with a saturating 
concentration of A1 receptor agonist N6-cyclopentyladenosine (CPA) alone and in 
combination with the positive enhancer PD81’723. Moreover, the degree of receptor 
internalization, produced by CPA concentration at, or close to, a saturation level, was 
magnified in the presence of PD81’723 (Klaasse et al. 2005). It is known that PD81’723 
exhibits its allosteric effects primarily by increasing agonist affinities and thereby increasing 
receptor occupancy (Bruns and Fergus 1990). However, the high intrinsic efficacy of the 
compound that has also been reported, seems to be confounding in this context (Bruns and 
Fergus 1990). In line with these findings, an in vivo study by Li et al. (2004) showed that 
repeated oral administration of the oral allosteric modulator T62, which belongs to the same 
chemical class as PD71’723, produces tolerance in rats with neuropathic pain. 
It could be argued that desensitization of the functional response observed in our experiments 
happens downstream of the receptor at the effector level and not at the level of the receptor 
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itself. In our case, we find this highly unlikely, because desensitization of the effector system 
should be activation-dependent. Since the pretreatments used differ only in the way 
(allosterism vs. orthosterism), but not the degree of receptor activation, the decreased response 
to agonism should be seen in both treatments, were it due to desensitization of the effector, 
which is not the case. This is further corroborated by the fact that we did not see a change in 
responsiveness of adenylyl cyclase to direct Gi/o-protein activation by mastoparan in 
desensitized cells, when compared to control. 
Although the main findings, showing that GS39783 is not prone to inducing receptor 
desensitization, are the same in both assay systems, we have also come across differences 
between the two experimental setups. Namely, in the recombinant cell line, 10 µM GS39783 
has no influence on the 100 µM GABA-induced desensitization of the GABAB response, 
regarding both the decrease in GABA potency as well as its maximal inhibition (Fig. 1, Table 
1). However, in the primary neurons it seems that 1 µM GS39783 prevents desensitization 
induced by a saturating concentration of R(-)-baclofen (Fig. 4, Table 2). Another divergence 
between the two systems is a decrease in the number of receptors at the cell surface (Bmax) 
that correlates with functional desensitization found in the recombinant cell line (Fig. 2) and 
no such decrease in the Bmax in the neurons upon receptor desensitization. This is in 
agreement with previous findings, Gonzales-Maeso et al. (2003) having shown receptor 
internalization to underlie functional desensitization of the GABAB receptor in a recombinant 
cell line similar to ours. Also, our inability to observe a decrease in receptor number at the cell 
surface in the cultured cortical neurons upon desensitization is in line with a report by Perroy 
et al. (2003). These differences might reflect distinctive processes of desensitization in the 
two examined systems. Several diverse mechanisms of GABAB receptor desensitization have 
been proposed in the literature. So far it has been undisputed that it does not involve β-arrestin 
recruitment, which is a part of desensitization pathways for most GPCRs. Numerous 
mechanisms of GABAB receptor desensitization have, however, been proposed: degradation 
 84 
 
 
 
 
of the receptors at the cell surface (Fairfax et al. 2004), regulation of G-protein-receptor 
coupling by endogenous regulator of G-protein signaling proteins (Mutneja et al. 2005), 
internalization (Gonzales-Maeso et al. 2003; Laffray et al. 2007), phosphorylation-
independent G-protein receptor kinase 4 regulation without changes in the receptor number 
(Perroy et al. 2003), protein kinase A-mediated phosphorylation as stabilization of the 
receptor at the cell surface (Couve et al. 2002) and a co-regulation mechanism by NEM 
sensitive factor and protein kinase C (Pontier et al. 2006). It is possible that the varying 
expression levels of intracellular regulatory proteins (that are a part of the “desensitization 
machinery”) in the two types of cells examined in this study give rise to the abovementioned 
differences. 
The main finding in this study i.e. that activation involving allosteric modulation by GS39783 
enhances GABAB receptor signaling but does not promote desensitization, is reminiscent of 
agonist directed  trafficking, a phenomenon described for various GPCRs, which involves the 
ability of different agonists activating different transduction pathways by acting upon the 
same receptor (reviewed in Urban et al. 2007). The prolonged presence of an orthosteric 
agonist both stimulates the receptor and promotes receptor desensitization. However, the 
change in the receptor conformation induced by the binding of an allosteric modulator 
apparently enhances only the signaling of the GABAB receptor, but does not lead to receptor 
desensitization. 
To conclude, in this study we have shown that, according to the expectations, the positive 
allosteric modulator GS39783 has no propensity for producing desensitization of the GABAB 
receptor, a key mechanism that underlies tolerance. To our knowledge, this is the first study 
demonstrating that it is indeed possible to enhance receptor function with allosteric 
modulation, to the same extent as with agonists alone, without inducing receptor 
desensitization. This confirms that positive allosteric modulation as a therapeutic principle 
may be advantageous over classical receptor activation by agonists. 
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5.3.1. Abstract 
It has been estimated that only 15% of the compounds classified as silent GPCR antagonists 
are indeed devoid of either positive or negative intrinsic efficacy. Considering that 40% of all 
drugs on the market target GPCRs mainly as orthosteric ligands, elucidating their true nature 
is becoming increasingly important. While agonism can be demonstrated using appropriately 
sensitive experimental setups, the detection of  inverse agonism can be limited by a low 
degree of constitutive activity in many assay systems. 
In this study, changes in ligand behavior upon a lasting pretreatment with GABA, that 
induced receptor desensitization, were observed, measuring the second messenger cAMP in a 
GABAB receptor-expressing recombinant cell line. The GABAB partial agonist 2-OH-
saclofen lost its ability to inhibit 7β-forskolin-induced cAMP production upon GABA-
pretreatment. The “silent” antagonists CGP62349, CGP52432, CGP56999 and SCH50911, on 
the other hand, stimulated 7β-forskolin-induced cAMP production under these conditions. 
The inverse agonism of CGP56999 was inhibited by the efficacy-deficient 2-OH-saclofen, 
proving it was truly mediated through the orthosteric site of the GABAB receptor. Finally, the 
positive allosteric modulator GS39783, which previously only marginally inhibited cAMP 
production, suppressed it by 60% both alone and in the presence of the competitive antagonist 
2-OH-saclofen, thus GS39783 became an allosteric agonist at desensitized GABAB receptors. 
These changes likely reflect adaptations in the mechanisms of GABAB receptor 
desensitization and may be important in the elucidation of intrinsic ligand efficacies as well as 
for the consequences of chronic drug treatment. 
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5.3.2. Introduction 
Chronic drug treatment often brings about not only receptor desensitization (the main cause of 
tolerance), but also other adaptations and changes as a response to it. In this study, we report 
apparent changes in efficacies of GABAB receptor ligands after a lasting desensitizing 
pretreatment with a saturating concentration of GABA. 
According to the two-state model of receptor activation (reviewed by Leff 1995), it is 
assumed that a given receptor exists in at least two interchangeable conformations: the resting 
(R) and activated (R*) state. The equilibrium between the two states can be described with an 
equilibrium constant L. Spontaneous conversion from R to R* without agonist binding is the 
basis for constitutive receptor activity, also known as basal or ligand-independent signaling, a 
concept that was first proposed by (Costa and Herz 1989). An agonist has a high preferential 
affinity for the activated state R* and upon binding to the receptor shifts the equilibrium 
toward it. Partial agonists do the same, only to a lesser extent (due to a smaller intrinsic 
efficacy). On the other hand, compounds with inverse agonistic properties favor binding to the 
inactive state of the receptor, thus pushing the R ↔ R* equilibrium toward the inactive state 
R. The prerequisite for detecting inverse agonism is a certain degree of constitutive receptor 
activity. Neutral (or silent) antagonists do not distinguish R from R* and therefore do not 
affect the equilibrium between the resting and the active state. It is important to note that the 
display of inverse agonism is conditional and not a molecular property in itself. Although 
there is a molecular mechanism that underlies inverse agonism, not observing it 
experimentally does not mean that the examined compound does not have negative efficacy. 
Instead, it is often the case that the experimental system used for elucidating the “true” 
valence of a ligand lacks constitutive activity, precluding the detection of negative efficacy. 
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Constitutively active mutant receptors (CAMs) mimic, at least to some extent, conformational 
changes induced by agonist binding to a WT receptor.  It is suggested, that a structural 
“constraint” keeps WT receptors in the resting state in the absence of an agonist, whereas in 
CAMs a mutation releases such a constraint and brings about receptor activation. These 
mutations in CAMs can be either artificially inserted or they can occur spontaneously in 
diseases (Seifert and Wenzel-Seifert 2002). Generation of CAMs has been shown to be very 
useful in detecting the negative efficacy of many inverse agonists (for reviews see Seifert and 
Wenzel-Seifert 2002; Cotecchia et al. 2003). It has been estimated that only 15% of all the 
compounds usually considered silent antagonists are indeed silent, the other ones having 
either a low partial agonistic or inverse agonistic properties (Strange 2002; Milligan 2003; 
Kenakin 2004). 
Considering a large number of clinically used inverse agonists acting upon GPCRs, a broad 
pharmacotherapeutic relevance of inverse agonism is implicated, including the treatment of 
hypertension, heart failure, type I allergies, opiate overdose, depression and schizophrenia 
(see Seifert and Wenzel-Seifert 2002 for a review). For example, it is known that true silent 
antagonists of µ-opioid receptors produce fewer adverse effects such as withdrawal 
symptoms, compared to inverse agonists (Sadee et al. 2005). In similar lines, atypical 
antipsychotic agents, which mostly act as inverse agonists on serotonin 5-HT2C and 5-
HT1A/B/D, are generally considered to be more effective in treating symptoms of schizophrenia 
than the typical antipsychotic drugs, that are mainly found to be neutral antagonists (Greasley 
and Clapham 2006).  
For these reasons and since the intrinsic efficacies of ligands are conditional, it is important to 
test them in adequate experimental settings. In this study, we report changes in ligand 
behavior after persistent activation of the GABAB receptor with GABA, which induced 
desensitization. Measuring cAMP, the second messenger of GABAB receptor activation, in a 
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recombinant cell line, we have observed compounds that were previously believed to be silent 
(or neutral) antagonists having inverse agonistic properties, a partial agonist became a silent 
antagonist and the positive allosteric modulator GS39783, that was previously shown to only 
marginally inhibit cAMP accumulation (Urwyler, Gjoni et al. 2005), significantly decreased 
cAMP in a manner of an allosteric agonist. Such changes are of potential importance because 
of functional consequences following a continuous drug treatment. 
 
5.3.3. Method description 
Materials: GS39783, CGP56999, CGP52432, CGP54626, SCH50911 and 2-OH-saclofen 
were available in-house. CGP56999, CGP52432, CGP54626, SCH50911 and 2-OH-saclofen 
were freshly dissolved in the assay buffer before each experiment. The stock solution of 
GS39783 was made up in DMSO and was further diluted in the assay buffer. 
 
Adenylyl cyclase assays in a recombinant cell line stably expressing GABAB receptors: A 
stable CHO cell line co-expressing human GABAB(1b) together with rat GABAB(2) (Urwyler et 
al. 2001) was cultured in Dulbecco's modified eagle medium (DMEM, glutamine-free, 
Invitrogen, Basel, Switzerland) supplemented with 10% fetal calf serum, 20 µg/ml L-proline, 
500 µM glutamine, 1 mg/ml geneticin, 250 µg/ml zeocin. The cells were grown to 80–90% 
confluency in 15 cm cell culture dishes. Prior to the cAMP measurement, they were treated 
with 100 µM GABA diluted in the cell growth medium for 2 hours. After the pretreatment, 
cells were washed twice with PBS. The cAMP accumulation experiment was then performed 
as has been described previously (see Sections 5.1. and 5.2. for details). 
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5.3.4. Results 
The partial agonist 2-OH-saclofen becomes a silent antagonist at desensitized GABAB 
receptors. It was shown previously that the GABAB receptor desensitized after a 2h 
incubation with a saturating concentration of GABA (see Gonzales-Maeso et al. 2003 and  
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Fig. 1. The partial agonist 2-OH-saclofen loses its efficacy at desensitized GABAB receptors. 
Measurement of the inhibition of 7β-forskolin-stimulated cAMP formation in recombinant cells stably 
expressing the GABAB receptor: a comparison between control (no pretreatment, filled squares) and 
desensitized conditions (2h pretreatment with 100 µM GABA, open squares). Data on the graph 
represent mean ± SEM (quadruplicates) of a typical experiment that was performed three times. 
 
 
Section 5.2.), which was apparent as a decrease in agonist potency to inhibit 7β-forskolin-
induced cAMP production as well as its maximal inhibitory effect. In this assay system 2-OH-
saclofen was found to be a partial agonist i.e. it inhibited 7β-forskolin-stimulated cAMP 
production to a maximal extent that was less than the one obtained by GABA (Urwyler, Gjoni 
et al. 2005). However, upon GABAB receptor desensitization, induced with a two-hour 
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pretreatment with a saturating concentration of GABA, the compound completely lost its 
ability to inhibit production of cAMP, suggesting that it became a silent antagonist (Fig. 1). 
 
The positive allosteric modulator GS39738 becomes an allosteric agonist in a 
desensitized recombinant system. Interestingly, the intrinsic efficacy of the allosteric 
modulator GS39783 increased after GABAB receptor desensitization, i.e. the compound 
inhibited cAMP production on its own (Fig. 2). The pEC50 of GS39783 was found to be 5.88 
± 0.11 (mean ± SEM, N=8), which is in alignment with the previously measured pEC50 of 
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Fig. 2. The positive allosteric modulator GS39783 acts like an allosteric agonist upon desensitized 
GABAB receptors (2h pretreatment with 100 µM GABA). 2-OH-saclofen has no effect on the 
concentration-response curve of GS39783. Measurement of the inhibition of 7β-forskolin-stimulated 
cAMP formation in recombinant cells stably expressing the GABAB receptor. Filled squares: GS39783 
alone, open diamonds: GS39783 + 100 µM 2-OH-saclofen, filled line: 100 µM 7β-forskolin control, 
dotted line: basal cAMP level. Data on the graph represent mean ± SEM (quadruplicates) of a typical 
experiment that was repeated four times. 
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GS39783 as a positive modulator under normal conditions (Urwyler et al. 2003). Unlike in 
non-pretreated cells, where GS39783 only slightly inhibited 7β-forskolin-stimulated cAMP 
production (Urwyler, Gjoni et al. 2005), in desensitized cells GS39783 maximally inhibited 
cAMP production by 60 ± 4.7 % (mean ± SEM, N=8). 
To make sure that the increase in efficacy of GS39783 was not a result of an effect of GABA 
left from the pretreatment due to insufficient washing, the concentration-response curve of 
GS39783 was measured in the presence of 100 µM 2-OH-saclofen, which could now be used 
as a (silent) competitive antagonist under these conditions (see above). This concentration of 
2-OH-saclofen is close to saturating (Urwyler, Gjoni et al. 2005) and sufficient to antagonize 
potential residues of GABA in the assay buffer. The concentration-response curve of 
GS39783 in desensitized cells was the same in the presence and the absence of 2-OH-
saclofen, confirming that the phenomenon of increased efficacy of GS39783 was indeed due 
to the compound only and demonstrating that it was not mediated via the orthosteric binding 
site (Fig. 2). 
 
Compounds known as silent antagonists become inverse agonists at desensitized GABAB 
receptors. The compounds CGP56999, CGP62349, CGP52432, CGP54626 and SCH50911, 
that were previously shown to be either devoid of any intrinsic efficacy or, in the case of 
CGP52432, to marginally increase cAMP stimulation in the same recombinant cell line that 
was used in this study (Urwyler, Gjoni et al. 2005), acted as inverse agonists upon a 
continuing exposure to GABA leading to GABAB receptor desensitization (Fig. 3). The 
potencies of these compounds and their maximal increase of cAMP stimulation are given in 
Table 1. The inverse agonistic efficacy of CGP56999 was antagonized with increasing 
concentrations of 2-OH-saclofen (Fig. 4), which proves that the effects were mediated via its 
binding to the orthosteric site of the GABAB receptor. 
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Fig. 3. CGP56999 (open squares), CGP62349 (filled diamonds), CGP52432 (open triangles) and 
CGP54626 (open circles) act as inverse agonists upon desensitized GABAB receptors (2h pretreatment 
with 100 µM GABA). cAMP measurement in a stable cell line expressing the GABAB receptor. 
Dotted line: 100 µM 7β-forskolin control. Data on the graph represent mean ± SEM (quadruplicates) 
of typical curves done at least three times; see Table 1 for potencies and maximal effects. 
 
 
ligand pEC50 EC50 maximal effect (% of 7β-forskolin control) N 
CGP56999 8.40 ± 0.09 4.0 nM 161 ± 24 9 
CGP54626 8.43 ± 0.48 3.7 nM 259 ± 41 3 
CGP62349 8.41 ± 0.17 3.9 nM 279 ± 51 3 
CGP52432 7.14 ± 0.01 72 nM 216 ± 26 3 
SCH50911 6.01 ± 0.17 977nM 208 ± 28 3 
 
Table 1. The silent antagonists CGP56999, CGP54626, CGP62349 and CGP52432 behaved like 
inverse agonists in the desensitized GABAB stable cell line potentiating 7β-forskolin-stimulated cAMP 
production in desensitized recombinant cells stably expressing the GABAB receptor. Desensitization 
was induced by a two-hour pretreatment with 100 µM GABA. Typical curves are shown in Fig. 3. 
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Fig. 4. 2-OH-saclofen, which is devoid of intrinsic efficacy at desensitized receptors (open squares), 
antagonizes the inverse agonistic effect of 3 nM CGP56999 (filled squares). cAMP measurement in a 
recombinant cell line stably expressing the GABAB receptor. Desensitization was induced by a two-
hour pretreatment with 100 µM GABA. Dotted line: 7β-forskolin control (100 µM); full line: 7β-
forskolin 100 µM + 3 nM CGP56999. Data on the graph represent mean ± SEM (quadruplicates) of a 
typical experiment repeated three times. 
 
 
5.3.5. Discussion  
In this study, we report changes in ligand behavior of different GABAB receptor ligands upon 
persistent agonist treatment leading to receptor desensitization (Gonzales-Maeso et al. 2003 
and see Section 5.2.). We demonstrate that the compounds CGP62349, CGP52432, 
CGP56999, CGP54626 and SCH50911, originally considered as silent (or neutral) antagonists 
at the GABAB receptor, became inverse agonists, i.e. they stimulated cAMP production. 2-
OH-saclofen, a partial agonist in this assay system, lost its intrinsic efficacy and became a 
silent antagonist. Moreover, the positive allosteric modulator GS39783, which was previously 
shown to only slightly decrease cAMP on its own (Urwyler, Gjoni et al. 2005), significantly 
inhibited cAMP production in a manner of an allosteric agonist. 
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There were other reports in which silent GABAB receptor antagonists were claimed to be 
inverse agonists. Grünewald et al. (2003) have found that CGP54626 and SCH50911 
increased cAMP formation and Hirst et al. (2003) have seen it with CGP54626, SCH50911 
and CGP62349. In a recently published publication on constitutively active GABAB receptor 
mutants inverse agonistic properties were observed for CGP54626, CGP52432 and 
CGP55845 (Mukherjee et al. 2006). In addition, we have previously observed a trend toward 
inverse agonistic activity for CGP52432 in the same recombinant cell line, that was used in 
the present study, but under non-desensitized conditions (Urwyler, Gjoni et al. 2005). 
To prove that the increase in cAMP production in the presence of these compounds was a 
specific GABAB-mediated phenomenon, we took advantage of the loss of efficacy of 2-OH-
saclofen in desensitized cells (Fig. 1) and used it as a neutral antagonist to bring the 
CGP56999-stimulated increase of cAMP back to the level of 7β-forskolin control  (Fig. 4). 
According to the measured potencies of inverse agonists (see Table 1), all the compounds 
were weaker when compared to their binding affinities in control (non pretreated) membranes 
(Urwyler, Gjoni et al. 2005). This is suggestive of an increase in constitutive receptor activity 
in the sense that, according to the two-state model (Leff 1995), inverse agonists stabilize and 
prefer binding to the inactive receptor conformation, while agonists favor the activated 
receptor. Similar trends, with apparent lowering of inverse agonist potencies in response to an 
elevation of the degree of constitutive activity of the receptor, were also observed in reports 
mentioned above by Grünewald et al. (2003) and Mukherjee et al. (2006). An additional 
factor contributing to a decrease in inverse agonist potency might also be the decrease in 
receptor density (loss of receptor reserve) concomitant with receptor desensitization 
(Gonzales-Maeso et al. 2003 and see Section 5.2.). 
The detection of inverse agonism is possible only in an experimental system with a sufficient 
degree of constitutive activity (ligand-independent receptor activation). Apparently, upon a 
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continuous agonist treatment (100 µM GABA, 2h), which has previously been demonstrated 
to lead to GABAB receptor desensitization (see Gonzales-Maeso et al. 2003 and Section 5.2.), 
a phenomenon reminiscent of an increase in constitutive activity occurs, that enables detecting 
inverse agonistic properties of the abovementioned ligands. It seems likely that the increased 
constitutive activity reflects a change in receptor conformation after a prolonged agonist 
treatment. This finding is in concordance with a report on a constitutively active GABAB 
receptor mutant (Mukherjee et al. 2006), where it was found that a mutation of a single 
amino-acid residue, either near the binding pocket for orthosteric ligands on GABAB(1) 
subunit or near the binding site for the G-protein on GABAB(2) subunit, increased the 
constitutive activity of the receptor. 
Comparable effects of prolonged agonist treatments increasing constitutive receptor activity 
were reported for β2-adrenergic (Chidiac et al. 1996) and µ-, δ- and κ-opioid receptors (Liu 
and Prather 2001 and 2002; Wang et al. 2000 and 2007). 
Research on the µ-opioid receptor (MOR) revealed changes in ligand behavior upon receptor 
desensitization similar to ours, namely a loss of maximal efficacy of agonists upon morphine 
and DAMGO-induced desensitization. At the same time, the authors noted a more 
pronounced negative efficacy of inverse agonists (Wang et al. 2007). These effects were 
explained by interactions of the receptor with calmodulin (CaM). Apparently, CaM and the G-
protein both bind to the intracellular loop 3 (i3) of MOR (Wang et al. 1999). In the absence of 
an agonist, CaM is predominantly bound to i3, sterically hindering MOR-G-protein coupling, 
which keeps the receptor in an inactive (resting) state. Upon activation, however, and 
especially upon MOR desensitization, CaM dissociates from the receptor, enabling a more 
efficient receptor-G-protein coupling. This results in an enhancement of the constitutive 
activity of the receptor (Wang et al. 2000). This phenomenon, an increase of basal receptor 
signaling after prolonged exposure to agonists, was also proposed to be one of the 
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mechanisms responsible for development of opioid dependence (Wang et al. 1994; Wang et 
al. 2001). 
There is no evidence of the GABAB receptor binding to CaM. However, a similar mechanism 
as described above for MOR might be involved with other intracellular proteins interacting 
with the GABAB receptor (Bettler et al. 2004). On the other hand, it can be speculated that 
regulator of G-protein signaling (RGS) proteins, that were shown to play a role in determining 
the level of constitutive activity for other receptors, e.g. the 5-hydroxytryptamine receptors 
type 1A and 2A (Welsby et al. 2002; Ghavami et al. 2004, reviewed in Milligan 2003), might 
also play a role in the regulation of the GABAB receptor function. RGS proteins are GTPase 
activating proteins (GAPs). They increase the GTPase activity of the Gα subunit, i.e. they 
accelerate hydrolysis of Gα-GTP upon GPCR activation and thus act as a “switch” that 
controls the intensity, duration and specificity of the G-protein-mediated signal, also keeping 
the basal receptor activity low (see De Vries et al. 2000 for review). GAP activity of most 
RGS proteins is inhibited by phosphatydilinositol-3,4,5-triphosphate (PIP3) (Popov et al. 
2000). Another mechanism inhibiting the GTPase activity of RGS proteins involves a 
scaffolding protein 14-3-3 (Benzing et al. 2000), a protein that also binds to the C-terminal 
part of the GABAB(1) receptor subunit (Couve et al. 2001). In analogy to PIP3-dependent 
inhibition of RGS GAP activity, the inhibition by 14-3-3 could also result in an increase of 
basal receptor signaling. Findings by Grünewald et al. (2003), indicating that the coiled-coil 
domain of the GABAB receptor is crucial for maintaining an active receptor conformation in 
the absence of an agonist, are in line with the speculation that RGS proteins might play a role 
in determining constitutive activity of the GABAB receptor. 
The loss of efficacy of 2-OH-saclofen to inhibit 7β-forskolin-stimulated cAMP accumulation 
is also in line with the increase of constitutive activity following desensitization. In this case, 
the “window” for detecting partial agonism becomes smaller, while the one for inverse 
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agonism broadens (Fig. 5). The proportion of receptors in the inactive (R) and the activated 
state (R*) determines the width of the “window” between the bottom and the ceiling for 
detecting agonism and inverse agonism, respectively (reviewed in Milligan and Bond 1997; 
Negus 2006). 
The allosteric modulator GS39783 became an allosteric agonist at the desensitized GABAB 
receptor, i.e. it significantly inhibited 7β-forskolin-stimulated cAMP formation. This 
inhibition was shown to be an effect mediated via the allosteric binding site: it was not 
antagonized in the presence of 2-OH-saclofen, which could be used as a silent competitive  
 
 
 
Fig. 5. The window-shift for the detection of agonism, antagonism and inverse agonism upon a lasting 
agonist treatment is reminiscent of an increase of constitutive receptor activity. Silent antagonists 
become inverse agonists (A), partial agonists lose their efficacy to become silent antagonists (B) and 
full agonists lose their efficacy to become partial agonists (C) upon a lasting agonist treatment. Panel 
(1): control condition (low constitutive receptor activity); panel (2): after a lasting agonist pretreatment 
(higher constitutive receptor activity). Adapted from (Milligan and Bond 1997) and (Negus 2006), 
with permission from Elsevier. 
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antagonist tool under these conditions. It should be noted that the other “silent” antagonists, 
which had inverse agonistic effects, could not be used for that purpose because their 
stimulatory effects on cAMP production would have been confounding. This shows the 
importance of choosing adequate tools for addressing such situations.  
 The allosteric two-state model allows activation of the receptor by the binding of an allosteric 
agent alone (Hall 2000). This can be detected in cases of high intrinsic efficacy of the 
allosteric agent, for example the activation of the mGluR7 by its allosteric agonist AMN082 
in its own right (Mitsukawa et al. 2005). Another possibility for detecting receptor activation 
by an allosteric agent alone is using very sensitive experimental systems, e.g. due to a high 
degree of receptor reserve, in which even effects of ligands with low intrinsic efficacies can 
be discerned. For instance, the other positive allosteric modulator of the GABAB receptor 
CGP7930 (Urwyler et al. 2001), that has similar in vitro activity as GS39783, was found to 
significantly activate the receptor in the absence of an agonist in a system with a seemingly 
high receptor reserve (IP turnover) (Binet et al. 2004), while its inhibition of cAMP formation 
was only minor in our hands (Urwyler, Gjoni et al. 2005). 
However, the fact that GS39783 in this study significantly inhibited cAMP production (by 
60%), whereas it did so only marginally under non-desensitized conditions in the same assay 
system (Urwyler, Gjoni et al. 2005), requires an additional explanation. According to a model 
for the functioning of family 3 GPCRs proposed by Parmentier et al. (2002), GPCRs are 
“allosteric machines” that consist of two parts: the VFTM (that comprises the orthosteric 
binding site) and the 7TM (that usually contains the allosteric binding site). The two domains 
can both adopt either inactive or active conformations, allosterically interacting with each 
other. The adoption of the active state by the VFTM (for instance due to agonist binding) will 
increase the possibility for the 7TM to also assume the active conformation, leading to G-
protein stimulation. These allosteric interactions between domains can either be “loose”, as in 
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the case of mGluRs, or “tight”, as in the case of the GABAB receptor, possibly due to the lack 
of the cysteine-rich region between the VFTM and the 7TM. 
It was recently shown, in a study on deletion mutants of the mGluR5 lacking the VFTM that 
the positive allosteric modulator 3,3'-difluorobenzaldazine (DFB) directly activated the 7TM 
as an allosteric agonist. As DFB is usually devoid of intrinsic efficacy, the fact that it 
displayed allosteric agonistic properties was explained by the loss of the allosteric inhibition 
of 7TM by the non agonist-occupied VFTM, present at the WT receptor (Goudet et al. 2004). 
It can be speculated that, in our case, the long-term activation by GABA disrupted or 
weakened allosteric interactions between the orthosteric and the allosteric binding sites, 
allowing GS39783 to have an effect in its own right and activate the receptor directly via the 
7TM. In line with this assumption is a recent finding by (Dupuis et al. 2006), where it is 
shown that GS39783 is able to activate a point-mutated GABAB(2) subunit alone, by binding 
to a site in its 7TM. 
In conclusion, this is the first demonstration of apparent changes in behavior of both 
orthosteric and allosteric GABAB receptor ligands upon continuous agonist treatment, most 
likely due to conformational changes and an increase of constitutive activity of the GABAB 
receptor. Although the mechanism responsible for these actions needs to be clarified, this 
assay system can be useful for observing properties of GABAB receptor ligands under 
conditions mimicking a chronic drug treatment in vitro. 
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5.4.1. Abstract 
In this work we studied effects of the positive allosteric modulator GS39783 on GABAB 
receptors at a biochemical level in vivo.  Changes in extracellular levels of cAMP following 
GABAB receptor activation were monitored in the striatum of freely-moving rats using 
microdialysis. The locally applied GABAB agonist R(-)-baclofen concentration-dependently 
inhibited cAMP formation stimulated by a water-soluble forskolin analog (EC50 = 7.3 µM, 
maximal inhibition = 40%). The selective GABAB antagonist CGP56999 reversed R(-)-
baclofen-induced cAMP inhibition to control levels, but not higher. Orally applied GS39783 
lacked effects on its own, but together with a threshold concentration of R(-)-baclofen (1 µM), 
it significantly and dose-dependently decreased cAMP formation. Effects of GS39783 were 
revoked with CGP56999 showing dependence on GABAB receptor activation and suggesting 
allosteric modulation as a mechanism of action in vivo. Administered with a maximally active 
R(-)-baclofen dose, GS39783 failed to further inhibit cAMP formation. The data obtained 
with CGP56999 and the lack of effect of GS39783 alone suggest there is no detectable 
endogenous activation of the GABAB receptors controlling cAMP formation in rat striatum. 
To our knowledge, these results provide the first biochemical demonstration of in vivo activity 
of a G-protein coupled receptor positive allosteric modulator. 
 
Keywords: GABAB receptor, GS39783, R(-)-baclofen, allosteric modulation, cyclic AMP, in 
vivo microdialysis 
 
Abbreviations used: aCSF, artificial cerebrospinal fluid; cAMP, cyclic AMP; 7β-forskolin, 
7-deacetyl-7-(O-N-methylpiperazino)-γ-butyryl-forskolin; GPCR, G-protein-coupled 
receptor; IBMX, 3-isobutyl-1-methylxanthine; ns, not significant; RIA, radioimmunoassay; 
SPA, scintillation proximity assay.   
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5.4.2. Introduction 
G protein-coupled receptors (GPCRs) comprise one of the largest protein superfamilies and 
the most diverse form of transmembrane signalling proteins. It has been estimated that 1% of 
the mammalian genome encodes GPCRs and about 450 of 950 predicted human GPCRs are 
expected to be receptors for endogenous ligands (Takeda et al. 2002). They are most 
important drug targets, as almost 40% of all current therapeutic agents, mostly identified in 
ligand-binding assays, act upon GPCRs in a competitive manner to the natural ligand, i.e. as 
orthosteric drugs (agonists and competitive antagonists) (Hopkins and Groom 2002; 
Maudsley et al. 2005). However, more recent concepts of drug action and modern drug 
discovery technologies have raised interest in molecules acting at GPCRs through other sites 
or other mechanisms (Rees et al. 2002; Brink et al. 2004). 
Allosteric modulators are molecules that modify receptor function by binding to a site on a 
receptor that is distinct from the orthosteric site, which binds agonists and competitive 
antagonists. Positive modulators usually do not stimulate receptors by themselves, but 
synergistically enhance receptor activation produced by agonists. This means that they would 
act mainly in concert with physiological signalling in its temporal and spatial organization in 
vivo, i.e. act only when and where endogenous transmitter has been released. Therefore, 
positive allosteric modulators are expected to have a better side-effect profile than agonists 
which activate receptors independently of synaptic activity. They should also have less 
propensity for developing tolerance subsequent to desensitization, which is observed 
following continuous receptor activation with agonists. For these reasons, allosteric 
modulation of GPCRs as a therapeutic principle has been attracting considerable attention 
lately (Christopoulos and Kenakin 2002; Christopoulos 2002; Jensen and Spalding 2004; 
Soudijn et al. 2004). 
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GABAB receptors are metabotropic GABA receptors which belong to the class III GPCR 
group, together with the metabotropic glutamate receptors, the calcium-sensing receptor, and 
mammalian taste and odorant receptors (Pin et al. 2003). They directly couple negatively to 
adenylyl cyclase (Wojcik and Neff 1984) and modulate voltage-gated calcium channels and 
inwardly rectifying potassium channels (Lüscher et al. 1997). They are located both 
presynaptically and postsynaptically to inhibit neurotransmitter release and neuronal 
excitability, respectively (reviewed in Bowery et al. 2002). 
The selective GABAB receptor agonist baclofen was introduced into clinical practice more 
than 30 years ago for treating spasticity, for example that originating from spinal injuries and 
multiple sclerosis. Its use as a therapeutic agent or a tool in preclinical studies is, however, 
limited on account of its side-effects, such as sedative/hypnotic effects and muscle atonia (a 
severe side-effect for potential indications other than spasticity), as well as the development 
of tolerance upon chronic treatment. 
The first GABAB receptor-positive allosteric modulators, CGP7930 and GS39783, were 
discovered only recently (Urwyler et al. 2001 and 2003). They have been characterized 
extensively in vitro and were found to increase both the affinity and efficacy of agonists in 
many different assays (Urwyler et al. 2001 and 2003; Urwyler, Gjoni et al. 2005; Onali et al. 
2003; Binet et al. 2004; Chen et al. 2005; Olianas et al. 2005). CGP7930 and GS39783 have 
also been tested in behavioural models in vivo in which, according to expectations, they 
lacked the side-effects seen with baclofen (Cryan et al. 2004). They were found to 
synergistically increase the sedative/hypnotic effects of baclofen (with no such effect of the 
modulator alone) (Carai et al. 2004), to have anxiolytic properties (Cryan et al. 2004; 
Mombereau et al. 2004) and to reduce cocaine self-administration in rats (Smith et al. 2004). 
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However, so far the enhancement of GABAB receptor function by allosteric drugs has not 
been demonstrated at a mechanistic (signal transduction) level in vivo. The activity of GPCRs 
coupled to Gi proteins can best be monitored by measuring the inhibition of cyclic AMP 
(cAMP) formation stimulated by forskolin, which directly activates the enzyme adenylyl 
cyclase. Hashimoto and Kuriyama (1997) have demonstrated that measuring extracellular 
cAMP levels in the striatum of freely moving rats by microdialysis is a suitable means of 
monitoring the activation of GABAB receptors in vivo. We have therefore chosen this 
approach to show, for the first time, the biochemical effects of the positive allosteric 
modulator GS39783 on GABAB receptors in vivo. 
 
5.4.3. Materials and methods 
All experiments complied with the Swiss law on animal experimentation and were approved 
by the relevant local authorities. 
Chemicals: The sources of commercially obtained chemicals are given below. GS39783, R(–
)-baclofen and CGP56999 were available in house. R(–)-baclofen and CGP56999 were 
dissolved and diluted in aCSF containing 3-isobutyl-1-methylxanthine (IBMX) freshly before 
each experiment. GS39783 was suspended in cremophor EL, propylenglycol and H2O in a 
ratio of 15 : 10 : 75 (vehicle) to give a fine suspension after ultrasonication (20 min). 
Surgery: Male Wistar rats (280–350 g) were anaesthetized with isoflurane inhalation (3–5% 
for induction and 0.5–1% for maintenance; Forene®; Abbott AG, Baar, Switzerland) using a 
mixture of N2O and O2 (1/3 and 2/3 respectively) (Carbagas, Basel, Switzerland). The 
anaesthetized animal's head was shaved and the animal was placed in a Kopf stereotaxic 
apparatus. A midline incision was made to expose the skull. The stereotaxic coordinates of the 
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caudate–putamen (striatum) were determined from a rat stereotaxic atlas (Paxinos and Watson 
1986). All anterior–posterior and lateral measurements were made relative to bregma and the 
ventral measurements were taken from the dura surface (flat head, i.e. with bregma and 
lambda in the same horizontal plane). One home-made 4-mm probe was placed at + 0.2 mm 
anterior, + 3.0 mm lateral and − 7.4 mm ventral, and secured in place with two skull screws 
and acrylic dental cement. Additionally, a long screw was fixed in the cement by which to 
later connect the animal to the freely moving microdialysis system. In preliminary 
experiments in separate animals, the coordinates were confirmed by histological verification 
of the probe placement. Microdialysis probes were constructed in a concentric design using 
23-G stainless steel tubing (Coopers Needles Works, Birmingham, UK), vitreous silica tubing 
(Schmidlin AG, Neuheim, Switzerland) and Hospal AN69 hydrogel-type dialysis membrane 
(Hospal, Lyon, France) with an active length of 4 mm. They were implanted while perfused 
with artificial CSF (aCSF) (141 mM NaCl, 5 mM KCl, 1.25 mM CaCl2, 1.2 mM MgSO4, 
1.4 mM Na2HPO4, 0.25 mM NaH2PO4, pH 7.4) at a flow rate of 5 µL/min. After implantation, 
the perfusion was stopped, and the inlet and outlet arms were heat-sealed using plastic 
connectors. After surgery the rats were housed individually in plastic cages and allowed to 
recover for 24 h with free access to food and water, in a room with a 12 h−12 h dark–light 
cycle. 
Experimental procedure: Some 24h after surgery, the conscious rat was connected to the 
microdialysis system allowing free movement. The probe was perfused with aCSF containing 
1 mM of the phosphodiesterase inhibitor IBMX (Fluka, Buchs, Switzerland), at a flow rate of 
2 µL/min. After a 1h waiting period, samples were collected every 20 min over 400 min (total 
of 20 fractions), and then immediately frozen in dry-ice and stored at − 80°C pending 
analysis. 
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We employed an experimental paradigm with two cAMP-increasing stimuli, consisting of 
local application (through the microdialysis probe) of 30 µM of the water-soluble forskolin 
analogue 7-deacetyl-7-(O-N-methylpiperazino)-γ-butyryl-forskolin dihydrochloride (7β-
forskolin) (Calbiochem, VWR International, Luzern, Switzerland) over 10 min. The first 
(control) stimulus (S1), which was the same for all rats, was given at 80 min after the start of 
the baseline period. Subsequently, the perfusion was changed back to aCSF containing IBMX. 
The second stimulus (S2) was applied at 240 min (eight fractions later). S2 was either the 
same as S1 (control rats), or it served to measure effects of drugs on cAMP formation (treated 
rats). R(–)-baclofen and CGP56999 (10 or 30 µM) were applied locally through the 
microdialysis probe for 20 min before and for 10 min during S2. At 60 min before S2 (i.e. at 
180 min), animals received either vehicle or GS39783 applied orally. After S2, the perfusion 
fluid was changed back to aCSF containing IBMX and seven more samples were collected. 
Animals were killed at the end of the experiment. 
Quantification of cAMP levels: The amount of cAMP formed was quantified by 
radioimmunoassay (RIA) in a scintillation proximity assay (SPA) format in 96-well microtitre 
plates. A 10-µL sample was diluted with 25 µL aCSF containing IBMX and acetylated with 
4 µL acetic acid anhydride and triethylamine (1 : 3) prepared shortly before use. Then, 87 µL 
immunoreagent solution was added to each sample. This solution contained 17 µL rabbit anti-
succinyl cAMP serum (anti-cAMP (rabbit); Calbiochem) diluted 1 : 3000, 35 µL donkey anti-
rabbit IgG secondary antibodies coated at the surface of SPA beads, diluted according to the 
instructions for use (SPA PVT antibody-binding beads, anti-rabbit; Amersham Biosciences, 
Little Chalfont, UK), and 35 µL adenosine 3',5'-cyclic phosphoric acid 2'-O-succinyl-3-
[125I]iodotyrosine methyl ester as a tracer (approximately 185Bq; Amersham Biosciences). 
The plates were incubated at 20–25 °C for 15–20 h and then counted on a Wallac 1450 
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microbeta Trilux scintillation counter (Wallac Oy, Turku, Finland). Quantification of the 
cAMP formed was performed with the aid of an appropriate RIA cAMP standard curve. 
Data analysis: The results were analysed with Prism 3.03 software (GraphPad Software Inc., 
San Diego, CA, USA). To account for possible drifts in baseline, linear regression of the 
baseline fractions was calculated using fractions 1–4, 11, 12, 19 and 20. Baseline values 
acquired in this fashion were deducted from all 20 fractions. The cAMP levels (in fmol) in 
fractions 5–10 and 13–18 were used to calculate the area under the curves for stimulations S1 
and S2. S2 was divided by S1 to calculate the S2/S1 ratio. Using two cAMP-raising stimuli 
and calculating S2/S1 ratios enabled each animal to be its own control and thus compensated 
for interanimal variability, therefore increasing the accuracy of the method. The data obtained 
were expressed as mean ± SEM values and statistical analysis was performed using unpaired 
two-tailed t-test or one-way ANOVA followed by Dunnett's test. 
Recovery of cAMP in vitro: To determine the recovery of cAMP by microdialysis in vitro, the 
efficiencies of five microdialysis probes were tested at room temperature in a 0.5% 
methylcellulose bath containing 10 µM cAMP with constant aCSF perfusion at a flow rate of 
2 µL/min for 2 h. Dialysate fractions were collected every 20 min and cAMP concentrations 
were quantified as described above. Under these experimental conditions, the mean ± SEM in 
vitro dialysis recovery of cAMP was 12.0 ± 2.1%. However, in vivo values were not corrected 
for the in vitro recovery of cAMP. 
R(–)-baclofen probe recovery in vivo: In order to assess the R(–)-baclofen concentration that 
reached the extracellular striatal space, the in vivo retrodialysis recovery of R(–)-baclofen was 
determined for each experiment in which R(–)-baclofen (and no other drug) was applied, by 
measuring its concentration in aliquots of fraction 12. To this end, a GABAB radioligand 
binding assay using rat cortical membranes (described in detail in Urwyler et al. 2003) was 
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modified into a radioreceptor assay format. The assay mixture had a final volume of 100 µL. 
It contained 25 µL of the unknown sample or R(–)-baclofen standard, 1 nM[3H]-CGP62349 
(3.15TBq/mmol; American Radiolabeled Chemicals, St Louis, MO, USA) in 20 mM Tris-HCl 
buffer (pH 7.4, containing 118 mM NaCl, 4.7 mM KCl, 1.8 mM CaCl2, 1.2 mM KH2PO4, 
1.2 mM MgSO4, 5 mM D-glucose), rat cortical membranes (approximately 15 µg protein) and 
1.5 mg wheat germ agglutinin-coated SPA beads (Amersham Biosciences). The samples were 
incubated for 90 min at room temperature, before being counted in a Wallac 1450 Microbeta 
liquid scintillation counter. R(–)-baclofen concentrations in unknown samples were 
determined from the inhibition of radioligand binding with the R(–)-baclofen standard curve. 
The in vivo retrodialysis recovery of R(–)-baclofen was calculated on the basis of the 
difference between the concentrations in the perfusate and fraction 12. 
 
5.4.4.  Results 
Effects of R(–)-baclofen on cAMP formation. To assess the activation of the GABAB 
receptors in vivo, we established a concentration–response curve for the inhibition of 7β-
forskolin-stimulated cAMP formation by the agonist R(–)-baclofen. Baseline cAMP levels 
amounted to 27.2 ± 1.8 fmol (n = 94) in the first fraction collected (the first 20 min). 7β-
Forskolin (30 µM) applied through the microdialysis probe in the striatum induced peaks 
corresponding to an approximately 3-fold increase in cAMP levels. Control animals, which 
received two challenges of 30 µM 7β-forskolin through the probe and vehicle applied orally, 
elicited the same response for both S1 and S2, i.e. the S2/S1 ratio was 1 ± 0.05 (n = 10). 
Traces of cAMP efflux are shown in Fig. 1. Pre-infusion of R(–)-baclofen (1 µM to 2 mM) for 
20 min and oral application of vehicle did not induce a change in the basal extracellular levels 
of cAMP in the striatum. However, co-application of R(–)-baclofen through the probe with 
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Fig. 1 Traces of extracellular cAMP efflux in rat striatum in vivo. Control rats (solid line), mean ± 
SEM S2/S1 ratio: 1 ± 0.05 (n = 10 animals). Effect of 500 µM R(–)-baclofen (dotted line), S2/S1 ratio: 
0.61 ± 0.03 (n = 6 animals). 7β-Forskolin was perfused through the microdialysis probe twice for 
10 min (S1 and S2, black bar) and R(–)-baclofen for 20 min before and 10 min during S2 (grey bar). 
The vehicle [used for oral (p.o.) application of GS39783 in other experiments] was administered at 
180 min (arrow). To account for differences in basal values among animals, cAMP extracellular levels 
were expressed as a percentage of baseline (for the purpose of this graph only). 
 
 
30 µM 7β-forskolin inhibited the 7β-forskolin-induced cAMP increase in a concentration- 
dependent manner (Figs 1 and 2). The maximal inhibition was about 40% and the EC50 was 
7.3 µM (Fig. 2). This effect was antagonized by co-perfusion of 30 µM CGP56999 (Fig. 2, 
inset). The concentrations of R(–)-baclofen recovered in fraction 12 were 23.4 ± 1.8% 
(n = 27) of the applied concentrations, indicating that approximately 80% of the drug perfused 
entered the surrounding striatal tissue. 
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Fig. 2 Concentration–response curve showing effects of R(–)-baclofen on extracellular cAMP levels in 
rat striatum in vivo. R(–)-baclofen was perfused through the microdialysis probe for 20 min before and 
10 min during S2. Data are mean ± SEM S2/S1 ratios obtained from 4–6 animals per treated group and 
10 animals in the control group. *p < 0.05, **p < 0.01 versus control group (horizontal line) (one-way 
ANOVA followed by Dunnett's test). Inset shows effect of the GABAB antagonist CGP56999 on R(–)-
baclofen-induced inhibition of cAMP formation in rat striatum (checkered bar). CGP56999 (30 µM) 
was co-infused with R(–)-baclofen (200 µM) for 30 min before and during S2. Black bar, control; 
striped bar, 200 µMR(–)-baclofen alone. Values are mean ± SEM S2/S1 ratios obtained from five 
animals per treated group. **p < 0.01 (unpaired two-tailed t-test). 
 
Effect of GS39783. GS39783 applied orally at 100 mg/kg, without local R(–)-baclofen 
perfusion, failed to inhibit the 7β-forskolin-induced increase in cAMP levels (Fig. 3). 
However, when given at 10, 30 and 100 mg/kg together with a threshold concentration of R(–
)-baclofen (1 µM) applied locally through the probe, GS39783 inhibited the extracellular 
cAMP levels in a dose-dependent fashion (significantly by 23% at the highest dose tested) 
(Fig. 4a). This effect was successfully antagonized by co-perfusion of CGP56999 (10 µM) 
(Fig 4a). When applied simultaneously with a maximally active concentration of R(–)-
baclofen (500 µM), GS39783 was unable to further augment the maximal inhibition produced 
by R(–)-baclofen (Fig. 4b). 
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Fig. 3 Lack of effect of GS39783 (100 mg/kg p.o.) alone on 7β-forskolin-induced cAMP formation. 
Values are mean ± SEM of S2/S1 ratios in controls (n = 10) and animals treated with 
GS39783 100 mg/kg p.o. (n = 6). There was no significant difference between the groups (unpaired 
two-tailed t-test). 
 
5.4.5. Discussion 
Benzodiazepines, positive allosteric modulators of ionotropic GABAA receptors, have proven 
to be efficacious drugs in over 30 years of clinical use. On the other hand, positive allosteric 
modulators of metabotropic GABAB receptors have been discovered only recently (Urwyler et 
al. 2001 and 2003). For the reasons outlined in the introduction, such compounds might be of 
great therapeutic benefit in clinical indications such as pain, drug dependence and anxiety 
(Marshall 2000 and 2005; Vacher and Bettler 2003). In the present study we showed for the 
first time the enhancement of GABAB receptor function in vivo by a GABAB positive 
allosteric modulator (GS39783) at a biochemical level. The efflux of cAMP into the 
extracellular fluid in striatal tissue was monitored using microdialysis in freely moving rats 
(Hashimoto and Kuriyama 1997). GABAB receptors are well known to inhibit cAMP 
formation via coupling to Gi proteins. Therefore, the cAMP levels in the  
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Fig. 4 (a) Effects of GS39783 (10, 30 and 100 mg/kg p.o.) combined with 1 µMR(–)-baclofen and 
antagonization with 10 µM CGP56999 (both applied through the microdialysis probe). Values are 
mean ±SEM S2/S1 ratios obtained from 5–7 animals per treatment. *p < 0.05 versus 1 µM R(–)-
baclofen (one-way ANOVA followed by Dunnett's test); +p < 0.05 versus 1 µMR(–)-
baclofen + 100 mg/kg GS39783 (unpaired two-tailed t-test). (b) Effects of GS39783 (100 mg/kg p.o.) 
combined with 500 µMR(–)-baclofen. The groups not receiving GS39783 were injected with vehicle. 
Values are mean ± SEM S2/S1 ratios obtained from five animals per treated group and 10 animals in 
the control group. **p < 0.01 versus control group (one-way ANOVA followed by Dunnett's test); ns, 
not significant. 
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extracellular striatal space should represent events of signal transduction that are close to the 
mechanism of receptor activation. Our experimental paradigm included two cAMP-increasing 
stimuli (Fig. 1), which enabled each animal to serve as its own control, thus taking into 
account interanimal variability. The finding that the S2/S1 ratio was exactly 1 in control 
animals showed that the cAMP-producing capacity of the striatal tissue was not diminished 
after the first stimulus. 
The selective GABAB receptor agonist R(–)-baclofen significantly suppressed cAMP 
formation induced by the water-soluble forskolin analogue 7β-forskolin in a concentration-
dependent manner (Fig. 2). The EC50 obtained for R(–)-baclofen was 7.3 µM, a nominal value 
corresponding to concentrations in the perfusate. However, in the light of the finding that 
about 80% of R(–)-baclofen applied through the probe penetrated into the tissue (in vivo 
retrodialysis recovery), this value is in agreement with numerous in vitro studies showing that 
baclofen activates GABAB receptors in the low micromolar range. Taking into account that 
Hashimoto and Kuriyama (1997) have used racemic baclofen, the concentration–response 
curve obtained with the active enantiomer of the drug (Fig. 2) is also in reasonable agreement 
with their findings. Moreover, in our experiments R(–)-baclofen maximally inhibited cAMP 
formation by 40% (Fig. 2), which is also in line with the approximately 50% maximal effect 
reported by Hashimoto and Kuriyama (1997). The effect of R(–)-baclofen, at a concentration 
that significantly inhibited cAMP formation, was entirely antagonized in the presence of the 
potent and selective GABAB antagonist CGP56999 (Fig. 2, inset), further confirming that the 
inhibition of cAMP production is GABAB receptor mediated. 
To demonstrate modulation of GABAB receptors by GS39783, a threshold concentration of 
R(–)-baclofen (1 µM) was chosen, to give a sufficiently large window for detection of the 
effects of the orally co-applied modulator. Under these conditions, GS39783 significantly 
inhibited cAMP formation in a dose-dependent fashion (Fig. 4a). This effect was completely 
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antagonized by CGP56999 co-applied locally with R(–)-baclofen (Fig. 4a). Together with the 
finding that GS39783 did not inhibit cAMP formation on its own (Fig. 3) this is in line with in 
vitro data showing that the compound is not active in the absence of an agonist or when the 
agonist site is blocked by a competitive antagonist (Urwyler et al. 2003), and indicates an 
allosteric mechanism of action of the drug. 
The positive allosteric modulator GS39783 has been shown previously to enhance not only 
the affinity of agonists in vitro, but also their maximal efficacy (Urwyler et al. 2003). To 
examine whether GS39783 augments the maximal inhibition of cAMP formation by R(–)-
baclofen in vivo, we tested GS39783 in combination with a maximally active concentration of 
R(–)-baclofen (500 µM). However, under these conditions, GS39783 failed to further inhibit 
cAMP formation (Fig. 4b). The most likely interpretation is that production of cAMP in the 
striatum is under the control of GABAB receptors only in a limited number of cells, but in 
these the maximal inhibition is close to complete and therefore not amenable to further 
enhancement by a modulator. We have recently described a similar situation in a recombinant 
cell line (Urwyler, Gjoni et al. 2005). 
Without R(–)-baclofen, GS39783 failed to inhibit cAMP formation at the highest oral dose 
used (Fig. 3). This finding strongly suggests that striatal GABAB receptors are not activated 
by endogenous GABA to any measurable extent. The fact that antagonism of R(–)-baclofen, 
alone or in combination with GS39783, by CGP56999 brought the S2/S1 ratio to the control 
level but not higher (Figs 2 and 4) confirms that cAMP production is not detectably inhibited 
by endogenous GABA in the rat striatum under control conditions. It seems unlikely that 
GABAB receptors exist without any activation by endogenous GABA; we therefore conclude 
that in our paradigm activation by endogenous GABA occurred at a low intermittent level that 
was not experimentally detectable. Earlier in vivo microdialysis studies also failed to detect 
activation by endogenous GABA of GABAB receptors controlling striatal acetylcholine 
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release (Anderson et al. 1993; DeBoer and Westerink 1994). On the other hand, physiological 
(endogenous) activation of GABAB receptors has been demonstrated in other brain regions, 
for example in the hippocampus (Moor et al. 1998) or in the substantia nigra, where they 
control the firing rate of nigrostriatal dopaminergic neurones (Erhardt et al. 1999). A 
measurable activation of striatal GABAB receptors by endogenous GABA would have had 
confounding effects in our experiments, for example not allowing us to conclude whether 
GS39783 has any agonistic effect on its own or not. Therefore, its lack made it possible to 
demonstrate and characterize more clearly the in vivo efficacy of GS39783 in conjunction 
with the exogenously applied agonist R(–)-baclofen. 
In conclusion, this is the first time that the enhancement of GABAB receptor function (and to 
our knowledge of a GPCR in general) by an allosteric drug has been shown in vivo at the 
signal transduction level, using a biochemical marker (cAMP formation) that is tightly linked 
to receptor activation. The data obtained strongly suggest that GS39783 acts on GABAB 
receptors in vivo via the same mechanism that has previously been demonstrated in vitro, i.e. 
as a positive allosteric modulator. This study therefore indicates that this appealing 
therapeutic principle, fairly novel for GPCRs, translates from the in vitro situation into that of 
a living organism. 
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6. Outlook 
Allosteric modulators of GPCRs represent a novel type of ligands with great therapeutic 
potential and increasing possibilities for medicinal chemistry, especially in cases where the 
development of orthosteric ligands with sufficient selectivity is elusive (see Chapter 4, 
Section 4.1.). The field of GPCR allosteric modulation has rapidly expanded, which resulted 
in a growing number of reviews published on the subject in the past decade and an increasing 
number of newly characterized positive and negative allosteric modulators (see Chapter 4, 
Section 4.1.). The discovery of allosteric modulators has been made possible by the 
development of new HTS technologies e.g. functional assays in recombinant cell lines. Their 
further pharmacological characterization is challenged by the appropriate choice of counter-
screening assays, which is absolutely critical. 
There are still not many allosteric modulators on the market as therapeutic agents. However, 
there is an example of an allosteric agent that has been discovered in 1937 and has been in use 
in man for more than 50 years. It is the non-nutritive artificial sweetener cyclamate, 
frequently used as an additive in food industry. Cyclamate is an allosteric agonist that binds to 
the 7TM domain of the T1R3 receptor unit of heterodimeric sweet and umami taste receptors 
(Bertorelli and Czarnowski-Hill 1990; Xu et al. 2004). 
There are other examples of allosteric modulators that have entered clinical trials as 
treatments for several disorders. One such substance is the allosteric enhancer of the 
adenosine A1 receptors, which belongs to GPCR family 1 (or A), T62 (see Chapter 2 for the 
chemical name) which is potentially useful in the treatment of neuropathic pain (Pan et al. 
2001). It has so far been tested in healthy volunteers to facilitate dose finding and was planned 
to enter Phase II clinical trials in the first half of 2007 (source www.kingpharm.com). 
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Further, according to the corticosteroid receptor hypothesis of depression, an altered function 
of the hypothalamic-pituitary-adrenocortical (HPA) system results in an overactivity of 
central corticotropin-releasing factor (CRF) circuits among depressive patients, which can 
monitored by increased levels of cortisol and corticotropin in their sera. Since the 
corticotropin-releasing factor type I receptor (CRF1), a member of  GPCR family 2 (or B), 
has been identified as responsible for conveying the signal into cellular circuitries underlying 
depression (Holsboer 2000), many pharmaceutical companies were prompted to develop 
molecules to inhibit the activity of CRF1. One such compound was the negative allosteric 
modulator of CRF1 R-121919 (see Chapter 2 for the chemical name), an orally active brain-
penetrating non-peptide substance, that selectively binds to the CRF1 with high affinity 
(Grigoriadis et al. 2000). R-121919 went into clinical studies for treating stress and 
depression and has reached Phase II (Holsboer 2003). Although it was found to alleviate 
depressive symptoms without eliciting undesired endocrine effects, the clinical trials were 
discontinued due to potential liver toxicity. 
Regarding GPCR family 3 (or C), the positive allosteric modulator of the CaSR cinacalcet 
(see Chapter 2 for the chemical name), is the only allosteric drug currently on the market. Its 
calcimimetic actions are utilized in alleviating primary and secondary hyperparathyroidism, a 
common and life-threatening complication of chronic kidney disease that can lead to 
cardiovascular calcification. The plasma concentration of ionized calcium (Ca2+) is a primary 
regulator of bone homeostasis mainly through its action on parathyroid hormone (PTH), 
which acts on kidney, by increasing renal Ca2+ reabsorbtion, and on bone to increase plasma 
Ca2+ levels. Elevated concentrations of plasma Ca2+, in turn, depress the secretion of PTH. 
This regulation is mediated via the CaSR in the parathyroid gland, which is downregulated in 
chronic renal failure. The positive allosteric modulator of CaSR cinacalcet can counteract the 
downregulation of CaSR by making the receptor more sensitive to the plasma Ca2+ 
concentrations, thus meeting the needs of patients with renal failure. Negative allosteric 
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modulators of CaSR such as NPS2143 and Calhex231 (see Chapter 2 for chemical names), in 
contrast, act as calcilytics and were found to stimulate PTH secretion (Nemeth et al. 2001; 
Petrel et al. 2003). However, since PTH in osteoporotic patients has anabolic activity on bone, 
effects of NPS2143 were tested in ovariectomized rats (an animal model of osteoporosis). 
When co-administered with 17-β-estradiol, as prevention of bone resorption due to a 
prolonged increase of PTH in the serum, NPS2143 induced a net bone gain. Other orally 
active calcilytic agents were also found to increase serum PTH levels in rats, offering a new 
potential treatment for osteoporosis (Arey et al. 2005).  
Another example demonstrating a small gap between the clinical use of allosteric modulators 
and preclinical research concerning GPCR family 3 are positive allosteric modulators of  
group II mGluRs (mGluR type 2 and 3). The selective orthosteric agonist of group II mGluRs 
LY354740 (see Chapter 2 for the chemical name), a structural analogue of glutamate, was in 
clinical trials for anxiety. Although its anxiolyic effects have been shown in many paradigms 
in human patients (Pilc 2003; Grillon et al. 2003), it had a limited oral availability (Johnson et 
al. 2002). This was circumvented by using a prodrug approach, which resulted in the peptidyl 
prodrug LY544344 (see Chapter 2 for the chemical name), that also displayed an anxiolytic 
profile in humans (Kellner et al. 2005). An alternative option for circumventing the problem 
of poor bioavailability of the mGluR2/3 agonist LY354740 was the development of selective 
positive allosteric modulators. A great number of compounds have been developed (Ritzen et 
al. 2005), some of which have been shown effective in animal models for anxiety and 
schizophrenia, indicating that clinical efficacy of positive mGluR2 modulators may be a 
reality in the future. 
Considering the continuous extensive use of functional assays in GPCR screening 
technologies in drug discovery programs of pharmaceutical companies, there is little doubt 
that even more allosteric ligands will be discovered and characterized in the following years.  
Subtype-selective allosteric ligands will continue being useful tools in in vivo investigations 
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of the (patho)physiological roles of GPCRs. However, the next challenge for medicinal 
chemistry will be designing new allosteric ligands with improved properties such as high 
affinity and bioavailability. 
Experiments conducted in this study investigated different aspects of prototypal positive 
allosteric modulators of the GABAB receptor. Even though CGP7930 and GS39783 have 
proven to be useful as tools for investigating GABAB receptor function both in vitro and in 
vivo (see Chapter 4, Section 4.3.), their wider use was restricted to some extent due to their 
relatively low potencies (in the µM range) and limited pharmacokinetic properties. 
Improvement of properties of these prototype allosteric ligands, i.e. higher potency and 
bioavailability, are crucial for the development of a new generation of therapeutic agents 
targeting the GABAB receptor. 
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